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INTRODUCTION 
 
 The skin is the body’s largest and thinnest organ, with a surface area of  
1.7 m2 and accounts for 16% to 20% of the total body weight. It forms a self-
repairing and protective boundary between the body’s internal environment and 
the external environment. Skin plays an important role in the excretion of water 
and salts, control of body temperature, synthesis of important chemicals and 
hormones, and as a sensory organ. 1 
 
 The skin continuously exposes to microbial pathogens, in order to prevent 
infection, cells within the epidermis and dermis have produced several innate 
strategies. The skin uses one of the Primary mechanisms in the early stages as 
immune defense by the synthesis, expression and release of antimicrobial 
peptides. The colonization by many pathogens were prevented by the skins 
normal microbial flora, pH, and chemical defenses (high salt and acidic 
environment) .1 
 
 Normal flora (also called "indigenous microbiota") refers to the diverse 
group of microbial population that every human being harbors on his/her skin and 
mucous membranes. Although there are many species of normal flora, these 
microbes typically fall into one of the two categories resident flora and transient 
flora. 4 
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Resident Flora 
 These organisms are life-long members of the body's normal microbial 
community and are very closely associated with a particular area. When disturbed, 
they again re-establish themselves. For example, Escherichia coliis a resident 
flora of the intestine. They do not cause harm; rather they have beneficiary effect 
on the host. 4 
 
Transient Flora 
           The transient flora consists of microorganisms that inhabit the body surface 
or mucous membrane temporarily for a short interval. Many of the transient flora 
are potential pathogens which may cause disease under certain conditions, e.g. 
Pneumococcus and meningococcus in nasopharynx. In hospitals, patients may 
acquire many resistant organisms as transient flora from the healthcare workers 
and hospital environment.4 
 
Skin microbiome  
 Microbiomes are thriving complex communities of bacteria, viruses and 
fungi, with approximately 1 million bacteria inhabiting each square centimeter of 
skin. That comprises mostly bacteria like Actinobacteria, Firmicutes, 
Bacteroidetes and Proteobacteria, with numerous subspecies thereof. 
Actinobacteria represents the largest phylum and includes Propionibacteriaand 
Corynebacteria; Firmicutes includes Clostridia and Bacilli, the latter including 
the Class Staphylococcus. The composition of these organisms depends on 
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sebaceous gland concentration,temperature and moisture content, also on host 
genetics and exogenous environmental factors. 
 
 These organisms are not only just commensals but also play a significant 
role in immunemodulation and epithelial health than previously expected. By 
understanding microbe–hostinteractions and the factors that lead to microbial 
colonization will provide greater insight into thepathogenesis of skin diseases, 
such as the role of Staphylococci in atopic eczema, and the development of new 
antimicrobial and promicrobial agents. 5,6 
 
 Bacterial skin infection is one of the most common clinical problem 
encountered in day to day clinical practice10.Pyoderma is the generic term used to 
describe any variant of superficial bacterial skin infection. 8 Pyoderma constitutes 
a major portion among patients attending dermatological clinics in India. 9 
 
Pyodermas may present in two major forms.  
 As a primary cutaneous infection  
 As a superimposed conditionin the previously diseased skin  
 
 Immunosuppression, atopic dermatitis, pediculosis, scabies, pre-existing 
tissue injury and inflammation are the various predisposing factors. The source of 
infection may be family members, hostel inmates, school mates, military barracks, 
medical personnel, or inanimate objects like clothes, floor, walls and instruments 
used in hospitals. Overcrowded places and hospitalization of the sick provide 
increased opportunities for dissemination of the organism2. 
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          The two important pyogenic organisms S. aureus and S. pyogenes are the 
etiological agents most commonly isolated,the former being more common than 
the latter. Besides these, other organisms that are occasionally isolated from 
pyoderma are Enterococci, Pseudomonas spp, E. coli, Proteus spp, 
Acinetobacterspp, and Klebsiella spp. 8 
 
 Most of the organisms isolated are found to be resistant to the antibiotics 
which were previously very effective so there is no response in many cases .The 
indiscreet and indiscriminate use of topical and systemic antibiotics leads to the 
antibiotic resistance. Multidrug resistant strains also possess the properties of 
transmissibility and virulence. As a result of introduction of newer antimicrobials 
and their extensive use, strains have been explodedthat they were resistant to 
greater number of antibiotics. Continuous use of antibiotics results in survival and 
spread of MRSA, ESBL producers and multidrug resistant Enterococci.11 With the 
emergence of MRSA, vancomycin and linezolid were commonly used antibiotics 
for MRSA infections. 
 
 Mupirocin (MUP), a topical antibiotic was used for the treatment of skin- 
and soft-tissue infections as well as for decolonization of nasal carriers 104. But the 
widespread use of mupirocin led to resistance among S.aureus, which was 
reported worldwide105 
 
 Ghadage D P&Sali Y A. (1999) et al states that most of the causative 
bacteria were found to be resistant to one or more antibiotics. They recommended 
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that while starting the antibiotic therapy, care should be taken to avoid 
unnecessary drug intake and so that in-vitro testing is essential for proper 
selection of antibiotics. Newer antibiotics must always kept in reserve for use only 
against resistant strains. Ideally, it would be better to carry out culture and  
sensitivity tests before prescribing antibiotics, but this is not always practical. 9 
 
 Rapid emergence of multidrug resistance among most of the Gram positive 
bacterial isolates complicates the management of pyoderma and demonstrates the 
need for more judicious use of antibiotics. 12,13Inspite of the fact that Pyoderma is 
easily treatable, it is known for their chronicity, recurrence, and other 
complications.Therefore timely recognition and prompt bacterial diagnosis with 
antimicrobial sensitivity is necessary for the effective management of pyoderma.12 
 
 By gaining knowledge about the pathogens and their antimicrobial 
susceptibility pattern, helps to prevent the emergence of resistant strains in future 
and guides the physicianin the management. Considering these aspects, the 
present study was conducted with the aimof isolation and identification of the 
causative organisms in different types of Primary and Secondary Pyodermas and 
detecting their latest antibiotic susceptibility pattern. 
  
Aims & Objectives 
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AIM AND OBJECTIVES 
 
 To isolate and identify the aerobic bacterial pathogens from skin lesions of 
patients with Primary and Secondary Pyodermas. 
 
 To study the antimicrobial susceptibility pattern of all the isolates. 
 
 To determine the antimicrobial resistance pattern of the most commonly 
isolated organism by phenotypic methods. 
 
 To detect the Mupirocin Resistance among MRSA isolates by phenotypic and 
genotypic method. 
 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
Historical aspects 
 Existence of microorganism was suspected by the roman philosopher 
Lucretius (about 98-55BC). Microorganism had been mentioned as a possible 
cause of disease by the roman Scholar, Marcus Varo in the first century BC. The 
physician Girolamo Fracrastro (1478-1553) suggested that the disease was caused 
by invisible living creatures. Fracrastro described “De contagione, 
contagiosismorbis et curatione (On Contagion, Contagious Diseases, and their 
Treatment)” in 1546. 14 Antony Von Leuwenhoek first observed the 
microorganisms accurately and reported it as bacteria. 15 
 
 Pus forming skin infections caused by coccal bacteria was first clearly 
defined by Tilbury Fox and Sabouraud in the late 19th century 16. In 1864, the 
contagious impetigo of children and Infants were described by Tilbury Fox. Sir 
Alexander Ogston gave the name Staphylococcus to the cocci due to the typical 
occurrence of grapelike clusters in pus culture. Von Recklinghausen first observed 
Staphylococci in human pyogenic lesions in 1871. 15 
 
 In 1874, cocci in chains were first observed by Billroth in erysipelas and 
wound infection, he named it as Streptococci. In 1881, Ogston isolated 
Streptococci from acute abscess and distinguishes it from Staphylococci.In1884, 
Rosenbach isolated cocci from human suppurative lesion and named it as 
Streptococcus pyogenes. 15 
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 In 1887,Bockhart described superficial pustular folliculitis which is 
characterized by small pustules at the follicular openings, hence named Bockhart 
impetigo. In 1889, Folliculitis decalvans was first described by Quainquad. 1 
 
EPIDEMIOLOGY 
 In 1960, Desai observed that more than 30% of Dermatology Outpatient 
department consists of infections like Pyoderma, superficial fungal infections and 
reported them as disease of poor economy. 19 
 
 In India, pattern of skin disease was due to various factors like poverty, 
malnutrition, overcrowding, poor hygiene, literacy and social backwardness. 20 
 
 Incidence of Pyoderma was more common in summer and monsoon. When 
the skin is exposed, abrasions or insect bites are more likely to occur, thus 
predisposing the susceptible children to these infections. 21 
 
 The relative incidence of clinical forms of pyoderma shows striking 
variation with age. Pyoderma occur most frequently among the economically poor 
children residing in tropical and subtropical climates28.Impetigo occurs more 
frequently in early childhood, although all ages may be affected29,31. 
 
 Bullous impetigo occurs characteristically in newborn and neonates. It was 
wide spread and contagious, although it can occur at any age. 29,30Ecthyma occurs 
in children or neglected elderly patients or in patients with Diabetes31. 
 
 Superficial folliculitis/Bockhart’s impetigo occurs more often in children, 
on Scalp30, 32 and on extremities, beard, buttock, axillary areas in adults31. 
Erysipelas was common in infants, young adults and older adults28. 
Staphylococcal scalded skin syndrome occurs largely in newborns and in children 
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younger than 5 years of age. It occurs rarely in older children and adults. Rarely 
distant focus consists of cutaneous infections or a septicemia33. 
 
 Chronic folliculitis of legs occurs in young Indian males, predominantly 
affecting age group of 15-30 years34. Deep folliculitis occurs in males between 
20-40 years. Hidradenitis suppurativa usually begins after puberty30.The peak 
incidence of pyoderma was high in children up to 10 years of age12.Peak 
incidence has also been reported in 2nd and 3rd decade followed by1st and 
4thDecade. 36 
 
 Pyogenic dermatoses occur usually due to secondary infection with 
Staphylococci and Streptococci. There is a higher incidence of pyoderma in the 
low socioeconomic strata21, 22, 23, 24 whereas factors like poverty, malnutrition, 
overcrowding and poor hygiene plays an important role22’23. 
 
 Impetigo was more likely to occur among children living in overcrowded 
homes and in poor hygienic situation. 25, 26 Often a history of similar lesion was 
present in other family members. 23, 24 
 
 Common predisposing factors of pyoderma include skin diseases, skin 
damage due to insect bites, minor trauma, surgical wounds, burn, retained foreign 
body, injections in diabetics or injection drug use and poor personal hygiene. In 
patients with poorly controlled diabetes, renal insufficiency, hematological 
malignancies, nutritional deficiencies, alcoholism and in those receiving 
Corticosteroid or cytotoxic therapy, resistance to infection with Staphylococci was  
reduced.22, 23, 26 
 
Classification of pyoderma  
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Pyoderma is classified into Primary and Secondary pyoderma. 
 
Primary pyoderma is a Pyogenic infection of the normal skin and its appendages 
and is caused by direct invasion of normal skin and tend to have more 
characteristic course and morphology.  
 
Secondary pyoderma arises in the previously diseased skin as superimposed 
condition and does not follow a characteristic course as it leads to either acute or 
chronic intermingling state of underlying skin disease.1 
 
TYPES OY PYODERMA 
Primary pyoderma Secondary pyoderma 
Impetigo 
Folliculitis 
Furunculosis 
Carbuncle 
Ecthyma 
Cellulitis 
Paronychia 
 
Eczema with secondary infection  
Infected pemphigus 
Infected contact dermatitis  
Infected psoriasis 
Trophic ulcer 
Infected scabies 
Infected wound 
Hidradenitis suppurativa 
 
IMPETIGO  
 Impetigo is a contagious superficial pyogenic infection of the skin, limited 
to the epidermis, forming pustules and crusty sores. Impetigo and folliculitis in the 
elderly is caused by Staphylococcus in contrast to impetigo in paediatric, which is 
usually caused by Streptococcus. Two clinical patterns of impetigo are 
recognized: bullous impetigo and non -bullous impetigo. 
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Bullous impetigo: 
 Bullous impetigo occurs most common in newborn and in older infants .It 
was mainly caused by phage group II S.aureus particularly strains 77 and 55, 
although Streptococcal bullous impetigo have also been reported38.It is 
characterized by rapid progression of vesicles to flaccid bullae around orifices. 
 
Non bullous impetigo: 
 It accounts for >70% of cases of impetigo and occurs in children of all ages 
as well as in adults. Previously it was believed that GAS is the most common 
etiological agent causing non-bullous impetigo. Recent studies showed that S. 
aureus being the most common organism isolated, followed by GAS. However it 
may be a mixed infection caused by both S.aureus and GAS38. Theinitial lesion is 
a transient vesicle or pustule that quickly evolves into a honey coloured crusted  
plaque that enlarges to greater than 2 cm diameter. 
 
FOLLICULITIS 
 Folliculitis is an inflammatory change confined to ostium or extends 
onlyslightly below it and heals without any scar formation37. It usually presents as 
crop of pustulesaffecting areas of skin with moist hair. S.aureus is the most 
common cause but can also caused by other organisms like Pseudomonas 
aeruginosa when associated with specific exposure like hot tubs and spar. 
 
FURUNCLE AND CARBUNCLE 
 A furuncle or boil is defined as an acute usually necrotic, infection of a hair 
follicle withS. aureus. The term carbuncle was derived from a Latin word mean 
for a small, fiery coal. It is defined as deep infection of a group of contiguous 
follicles with S. aureus, which causes inflammatory changes in the surrounding 
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and underlying connective tissues, including the subcutaneous fat. It occurs as an 
extremely painful lesion at the nape of the neck, the back, or thighs. 37 
 
ECTHYMA  
 Ecthyma is a characterized by the formation of adherent crusts beneath 
which ulceration occurs.  It is usually occurs as a consequence of neglected 
impetigo and classically evolves in impetigo occluded by footwear and clothing. 
S. aureus and GAS are the common causes. 37 
 
CELLULITIS  
                  Cellulitis is an acute inflammatory condition of the skin that extends 
deeper into the dermis and subcutaneous tissue, characterized by localized pain, 
erythema and swelling. GAS and S.aureus are the most common etiological agents 
isolated MRSA is rapidly replacing MSSA as acause of cellulitis in both inpatient 
and outpatient settings. 
 
HIDRADENITIS SUPPURATIVA 
 It is a chronic inflammatory, recurrent debilitating follicular disease usually 
begins after puberty. It involves apocrine bearing skin with a predilection for 
intertriginous areas, most commonly involves the genitofemoral area or axilla. 
S.aureus and CONS are most frequently isolated pathogen. 37 
 
PEMPHIGUS  
 The term Pemphigus was first described by Sauvages in 1760. Wichmann 
in 1971 described chronic bullous disease as Pemphigus. Pemphigus is a chronic 
autoimmune bullous dermatoses, characterized histologically by intraepidermal 
blister formation. 39 
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 Pemphigus is divided into two major subtypes depending on location of  
blisters in the epidermis. 
 Superficial                       Deep 
 Pemphigus foliaceus                     Pemphigus vulgaris  
 Pemphigus erythematosus            Pemphigus vegetans 
 
 It is mainly a disease of middle age group. Some Indian studies have found 
that men affected more frequently than women. In many studies, mean age of 
occurrence is 30-40 yrs, it was in accordance with Indian literature. 
 
 Pemphigus vulgaris presents as flaccid mucocutaneous blisters and have a 
tendency to rupture easily. Pemphigus was usually fatal prior to the advent of 
steroids and antibiotic therapy. 39 
 
 Infection is the most important complication in these patients attributes to 
disruption of epidermal lesions because of the disease itself and 
immunosuppression induced by treatment.  
 
 Many reports states that predisposition to infection is due to 
immunosuppressive therapy and immunocompromised state of the Pemphigus 
patients.If left untreated progression of the disease may lead to death due to 
secondary bacterial infection and sepsis. Staphylococcus aureus is the most 
common cause of bacterial infection. 40 
 
BULLOUS PEMPHIGOID 
 It is a sub epidermalimmunobullous disorder and predominantly a disease 
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 of elderly with age of onset between 69 and 83. It is an autoimmune blistering 
disease presents with large, tense, cutaneous blisters. Rupture of the bullae results 
in erosions, which is susceptible to bacterial infection. 39 
 
ECZEMA 
 Eczema is derived from Greek word meaning “to boil” 37. The term eczema 
and dermatitis generally regarded as synonyms39. Clinically eczema 
ischaracterized by itching, redness, edema, papulovesicule in acute stage, edema 
and scaling in subacute and dry lichenfied skin in the chronic stage37. Most case 
of eczema in infants and young children are atopic and nummular dermatitis 
occurs particularly in elderly males. 39 
 
 Skin of atopic patients of eczema carries high levels of S.aureus which 
correlate with severity of eczema. S.aureus releases a toxin with super antigenic 
actions and initiates a vicious circle in atopic eczema41. In most of the patients 
with atopic eczema even though there is an absence of skin lesion; colonization of 
S.aureus will be noticed due to altered immunological profile of atopic patients. 39 
 
 Innate immunity is compromised in atopic eczema due to reduction in 
keratinocyte derived antimicrobial peptides (cathelicidin, betadefensin 2 & 3) and 
neutrophil chemo attractant. 37,41 
 
PSORIASIS 
 Psoriasis is chronic inflammatory and proliferative condition of the skin, 
associated with systemic manifestation in many organ systems. 
 
 Fatima Zahra Elfatokeret al. (2016) states that Psoriasis is a chronic 
inflammatory skin disease which has been found to affect up to 5% of the world’s 
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population. The exact etiology is unknown concepts of pathogenesis indicate the 
genetic, immunologic and environmental factors. 42 
 
 Gudionsson.E.J. (2003) and Malbris.L.et al (2005) states that the chronic 
plaque form psoriasis is the most common type. 
 
 Association between psoriasis and tonsillitis was noticed 100 years ago, 
now it is well recognized that Psoriasis is triggered by Streptococcal infection. 37 
 
TROPHIC ULCER 
 The term “trophic” is derived from Greek word Trophe means nutrition. 
The American heritage medical dictionary 2007 states that trophic ulcer is “an 
ulcer due to impaired nutrition of the part”43. Recent studies states that no 
correlation between nutritional indices and development of trophic ulcer. 37 
 
 Now considerable evidence is there to suggest that this disease is due to 
infection. For successful management of chronic ulcer it is necessary to identify 
the etiology as well as local and systemic factors contributing to its non-healing 
nature. 41 
 
Etiology 
 Pyodermas are usually caused by Gram positive bacteria, which constitute 
majority of cases and less commonly by Gram negative organisms23.Among the 
Gram positive organisms, S.aureus is the most common organism isolated 
followed by CoNS, BHS and Enterococcus has also been isolated from few cases. 
 
 Various Gram negative organisms isolated include Pseudomonas spp, 
Klebsiella spp, Proteus spp, E.coli, and Acinetobacter spp23.In most of the cases 
infection is caused by a single Pathogen, although mixed infections may also 
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occur. Most of the mixed Infections are caused byS. aureus and Gram negative 
organism. 23, 24, 25 
 
STAPHYLOCOCCUS 
 Staphylococcus is the most common pathogen isolated from both primary 
as well as secondary pyoderma. 38 
 
 The genus staphylococcus is classified under the family 
Staphylococcaceae, order Bacillales in the phylum firmicutes according to 
volume3 of the revised Bergy’s manual of systematic microbiology.S. aureus is 
the most common human pathogen among the Staphylococci, although CONS has 
also been reported as the etiological agent by a few workers. 3 
 
 Staphylococcal skin lesions are characterized by the formation of pus 
containing lesions which often begin in hair follicles and spread to adjoining 
tissues. 25 
 
Mode of infection  
 May be exogenous from direct contact,airborne or cross infection in 
hospitals or endogenous from colonization. 
 
 S.aureus is found in the external environment  and in the anterior nares of 
25-35% of healthy adults .Other sites of Colonization  are intertriginous skin 
folds,the perineum, the axilla and vagina. 
 
 It was suggested that 10-20% of general population are persistent carriers 
of S.aureus with up to 50% of intermittent carrier and 20-30% non-
carrier37.Prevalence of nasal carriage in healthy adults is 27%37. A correlation has 
been noted between nasal flora and organisms causing pyoderma, high nasal 
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carriage contributes to recurrent pyoderma44.The rate of colonization was higher 
among HIV infected patients, insulin dependent diabetics, haemodialysis patients 
and those with damaged skin. 25 
 
 Factors which predispose to serious S.aureus infection includes defect in 
leucocyte chemotaxis, defects in opsonisation, skin injuries, presence of foreign 
bodies and chronic underlying diseases. 3 
 
Virulence factors of S.aureus1, 2 
Polysaccharide capsule Inhibits Phagocytosis 
 
Peptidoglycan 
 
Confers rigidity and resistance to cell wall. 
Induces  inflammatory response 
Activates complement,IL1,chemototactic to 
PMNs 
 
Teichoic acids 
 
Protects from complement mediated 
opsonization 
Species specific,mediates binding to 
fibronectin 
 
Protein A 
 
Affinity for Fc receptor of IgG and 
complement 
 
Adhesins 
 
Clumping factor B associated with S.aureus 
nasal colonization. 
 
Hemolysin and Leukocidin/ 
Panton valentine toxin 
 
Hemolytic and leukocidal activity 
 
Exfoliative toxin 
 
Scalded skin syndrome 
 
Enterotoxins: A-E, H& I 
 
Food poisoning{ 2-6 hours} 
 
Toxic Shock Syndrome Toxin I (TSST-
1); 
 
Toxic shock syndrome 
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Enzymes: 
Coagulase 
Clumping factor 
Catalase 
 
Hyaluronidase 
Staphylokinase/ fibrinolysin 
 Lipases 
Nucleases  
Penicillinase 
 
 
Converts fibrinogen to fibrin 
Able to bind fibrinogen 
Inactivate hydrogen peroxide and free 
radicals 
Breaks down connective tissue network 
Breaks down fibrin clot 
Breaks down lipids 
Hydrolyze DNA 
Hydrolyze Penicillin 
 
 
Pathogenicity:  
 The pathogenicity of Staphylococcal infection was attributed to the surface 
antigens present in the Staphylococcus aureus and contributing to its 
antiphagocytic property. These include exotoxins like alpha  toxin and leukocidin 
which are injurious to human  leukocytes. 80, 81 
 
 The presence of an extra cellular enzyme, coagulase plays a major role in 
 Pathogenesis. The mechanisms with which it operates are82 
 It promotes clot formation and then disturbs the functioning of phagocytic cell.  
 It is responsible for the deposition of fibrin over the surface of Staphylococci 
giving it antiphagocytic envelope.  
 Necrosis and abscess formation result from the formation of local thrombi.  
 
 The other enzymes like hyaluronidase and lipase, contribute a minor role in 
the pathogenicity of Staphylococcal infection.  
 
The mechanism of cutaneous infections were mainly due to  
a) Direct infections.  
b) Toxin mediated disease.  
c) Immunologically mediated disease.  
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Immunological response against Staphylococci : 
 Haemolysin and antileukocidin are the major antibodies against 
staphylococcal antigens. The passive transfer of these antibodies transplacentally 
provide protection against Staphylococcal infection during the first trimester of 
intrauterine life80. 
 
ANTIBIOTIC RESISTANCE AMONG  STAPHYLOCOCCUS AUREUS: 
 In the early 1940’s, Penicillin was introduced as drug of choice for 
treatment of serious Staphylococcus aureus infection. Resistant to penicillin was 
emerged in 1959 and it was due to acquisition of plasmid borne gene element blaZ  
encoding β -lactamase. 
 
 Penicillinase resistant penicillins (oxacillin, methicillin, nafcillin) were 
developed and introduced in1959 for clinical use. In 1960s ,with the emergence of 
methicillin-resistant strains of  S. aureus (MRSA) in  UK, the drug was rendered 
clinically ineffective. Resistant to methicillin was due to presence of PBP2a 
results from acquisition of chromosomal element known as SCC mec. S.aureus 
strains that contain SCC mec are termed MRSA and that lack this element 
MSSA.It was believed that  S.aureus  acquired the SCC mec transposon from a 
coagulase negative staphylococcal species S.sciuri which found on animals and in 
the environmemt.2 
 
 Methicillin resistant Staphylococcusaureus and Coagulase-negative 
Staphylococci (CoNS), were considered resistant to other β-lactam agents, ie, 
penicillin’s, β-lactam/β-lactamase inhibitor combinations, cephems (with the 
exception of the cephalosporins with anti-MRSA activity), and carbapenems.  
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 The  Panton -Valentine leukocidin is an important virulence factor in 
MRSA. 58 MRSA can cause infection ranging from simple furuncles to life 
threatening necrotizing fasciitis and pyomyositis. 58 In 1968, the first case  of 
MRSA was reported  in the United States .  MRSA  have remarkably developed 
resistance against variety of antibiotics including penicillins, cephalosporins, 
aminoglycosides, macrolides and quinolones57.MRSA was recognized initially in 
the health care setup, later MRSA  spread to  the community in 1980s. 55 
 
 Thereafter community acquired MRSA has been increasingly reported in 
skin and soft tissue infections in India and globally56. In India, MRSA prevalence 
overall increased from 12% in 1992 to 80.83% in 1997. 54 
 
Types of MRSA 
Healthcare-associated MRSA. Healthcare-associated MRSA (HA-MRSA) were 
isolated from the patients admitted to healthcare facilities such as nursing homes 
and long-term care facilities. HA-MRSA causes Healthcare-associated infections 
like bloodstream infections, urinary tract  infections, respiratory tract infections, 
surgical-wounds and device-associated infections. 45,46,47 
 
 Risk factors for acquiring HA-MRSA include previous admission to 
healthcare facilities, impaired immune system, use of multiple antibiotics, use of 
invasive medical devices and old age. 49 Genetically, the HA-MRSA carried SCC 
mec types I, II and III, which is  usually multidrug resistant  and tend to multiply 
slowly in culture. 49 
 
Community-associated MRSA 
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 In late 1980s, Community-associated MRSA (CA-MRA) strains were 
initially reported among individuals with no previous history of hospitalization 
living in remote communities in Western Australia. 51The initial report was 
followed by similar reports from USA, New Zealand, and later in Europe. 
Initially, CA-MRSA were mostly associated with skin and soft tissue infections  
such as impetigo, cellulitis, folliculitis and boils and the young patients are at risk. 
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 CA-MRSA are usually susceptible to non-beta lactam antibiotics which 
carry smaller-sized SCC mec types IV, V and VI.  CA-MRSA strains often 
express lower levels of resistance to oxacillin (MIC; 8–32 mg/L) and also 
multiply faster than HA-MRSA strains with significant shorter doubling time, 
which may help CA-MRSA to achieve successful colonization by enabling it to 
compete out the normal bacterial flora. 48 
 
Livestock-associated MRSA 
 Staphylococcus aureus is also an important cause of infections in live stock 
resulting in economic losses in the food industry. Livestock-associated MRSA 
(LA-MRSA) strains were initially identified because they were non-typeable by 
pulsed-field gel electrophoresis following digestion with Sma I restriction 
enzyme. Further molecular typing revealed that LA-MRSA defined   to a new 
lineage of MRSA that belonged to clonal complex 398 (CC398). 49 
 
 Although LA-MRSA ST398 was initially reported among livestock, 49,50it 
has also appeared in the community among human patients in contact with 
infected or colonized animals which was considered as a major risk factor for LA-
MRSA colonization. 50 
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 Other LA-MRSA lineages reported in humans include ST9, ST97 and 
ST43352. LA-MRSA has also caused invasive infections including endocarditis, 
osteomyelitis, and ventilator-associated pneumonia in humans. 52,53 
 
Detection and identification of MRSA 
 MRSA can be detected by both phenotypic and genotypic methods. The 
ideal method of detection of MRSA is by detection of mecA gene or its product 
PBP2a.Because of high cost and need expertise it was not performed in most of 
the clinical laboratories. 
 
 Kacou- N doube et al (2011) states that pcr is the gold standard method to 
detect mec A gene in MRSA.      
 
Methods of detection of MRSA 
Screening methods 
 With cefoxitin/oxacillin disc by disc diffusion method. 
 
Confirmatory methods 
 Oxacillin MIC detection (by broth dilution,agardilution,E-test method), 
oxacillin screen agar. 
 
Molecular methods 
 Detection of mecAgene or PBP2a protein (its protein products) 
Treatment options for MRSA infections 
 The emergence of methicillin resistance was accompanied by the 
development of resistance to most of the non-beta-lactam antibiotics and resulted 
in the reduction in options for treating infections caused by MRSA. 45 
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 In the 1980s, some MRSA strains were resistant to all available antibiotics 
except vancomycin. 59,60The situation was compounded by the emergence of 
strains that expressed reduced susceptibility to vancomycin in the late 1990s, 
followed by vancomycin-resistant S.aureus strains (MIC: 32 mg/L) in the USA 
and other countries. 60 
 
 The vancomycin-resistant S. aureus had apparently acquired vanA gene 
complex from vancomycin-resistant enterococci whereas vancomycin 
intermediate-resistant S. aureus strains have reduced susceptibility to vancomycin 
due to their thickened cell wall which is capable of binding vancomycin and 
reduce their diffusion into the cell. 61 
 
 Newer antibioticslike daptomycin, linezolid, tedizolid, telavancin, 
oritavancin, dalbavancin, ceftaroline and ceftobiprole have been developed 
against MRSA strains. 45 
Control of MRSA infections 
 Globally, there is increase in number of multidrug resistant pathogens in 
healthcare facilities as well as in the community. The constant threat that 
resistance to even the newly developed antimicrobial agents may develop makes it 
necessary that other methods for limiting the spread of multidrug resistant 
organisms, to be developed and implemented. Some of these approaches include 
active surveillance of resistant pathogens, antibiotic stewardship, and for better   
implementation of infection control methods. 45 
 
 The burden of multidrug resistant pathogens in healthcare settings will be 
reduced by Preventing infections. 62 
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 The main infection control interventions used against MRSA include 
screening, hand hygiene, contact isolation, cohosting and decolonization in 
addition to standard precautions. These procedures should be continued till 
patients become culture-negative for the target multidrug resistant pathogen. 45 
 
Topical agents to be used to reduce surface colonization of MRSA include the 
following:  
 Hand wash with 70% alcohol 
 Chlorhexidine gluconate, 4% (more active againstMRSA than MSSA) 
 Triclosan (soap) 
 Povidone iodine (equally active against MRSA and MSSA)86 
 
Mupirocin 
 Mupirocin (pseudomonas acid A), a polyketide antibiotic was naturally 
produced by Pseudomonas fluorescens strain NCIMB  10586 67,77. It has 
antibacterial activity against a wide range of gram-positive and gram-
negativebacteria, however many strains of Pseudomonas are resistant. Mupirocin 
is rapidly metabolized by the skin to an inactive, nontoxic substance, viz, monic 
acid, and thus appears to be ideal for use in patients with extensive areas of 
denuded skin. It is used topically for the treatment of skin infections, prevention 
of surgical site infections, and eradication of Staphylococcus aureus carrier 
state.79 
 
 Mupirocin was introduced into clinical practice in 1985, with mupirocin 
resistantS. aureus (MupRSA) was first reported in 1987. Resistance was classified 
into two categories:      
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 Low-level resistance, with MICs ranges from 8 - 256 µg/ml, and high-level 
resistance, withMICs of >512 µg/ml. Isolates with MIC ≤4 µg/ml were considered 
mupirocin susceptible. In most cases, High-level resistance was conferred by 
acquisition of the plasmid-borne gene mupA, which is a phylogenetically distinct 
isoleucyltRNA synthetase gene, with no affinity for mupirocin. mupB, a related 
gene, has also been shown to confer high-level resistance.76 
 
 Low-level mupirocin resistance was caused by point mutations in the 
native isoleucyl- tRNA synthetase gene (ileS). It may be associated with higher 
rates of recolonization after measures to eradicate S. aureus carrier state. 76 
 
 Many Studies on mupirocin resistance among S. aureus indicates that 
nearly all S. aureus isolates with high-level mupirocin resistance were mupA 
positive by polymerase chain reaction(PCR) .69,70 
 
 Isolates with low-level mupirocin resistance but positive for the mupA 
gene have been identified. In these isolates, the mupA gene was located on the 
chromosome and not on a plasmid71. Also, isolates that are mupirocin susceptible 
but mupA positive by PCR have been reported.  
 
 It was attributed due to a frameshift mutation in the mupA gene that 
inactivates the gene product72.  
 
 Isolates with the frameshift mutation revert to wild-type sequence and 
develop high-level mupirocin resistance at a high frequency. 
 
 Few isolates have been identified that demonstrate high-level mupirocin 
resistance but are mupA negative by PCR despite the use of multiple primer sets. 
These isolates may carry a novel mechanism of mupirocin resistance.75 The mupA 
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gene is typically located on mobile genetic elements, which likely facilitates the 
dissemination of this resistance mechanism. The mupA gene is typically plasmid 
mediated, and some of these plasmids are conjugative73,74 
 
 Insertion sequences have been identified flanking the mupAgene in 
plasmids, which might facilitate movement of the mupA gene between plasmids 
by recombination 74.  
 
 Retapamulin, a pleuromutilin antibacterial agent is a topical antibiotic 
effective against mupirocin resistant strains. Currently it was used against a 
variety of Gram positive pathogens associated with secondarily-infected 
dermatoses and secondarily-infected traumatic lesions. The pleuromutilins were 
potent inhibitors of protein synthesis in bacteria through the intervention of 
peptide bond formation by binding to the peptidyl transferase centre of the 50S 
ribosomal subunit. Retapamulin shows no target specific cross-resistance to other 
classes of antibiotics due to its unique mode of action .102 
 
Detection of mupirocin resistance 
 Multiple laboratory testing methods have been described for determining 
the MIC of mupirocin, including agar dilution, broth microdilution and E-test. The 
Clinical and Laboratory Standards Institute (CLSI) recommends using broth 
microdilution or disc diffusion for screening of high-level mupirocin-resistant S. 
aureus, and it only differentiates between high-level resistance and the absence of 
high-level resistance. 65 
 
 CLSI and the European Committee for Antimicrobial Susceptibility 
Testing (EUCAST) both recommends the  use of  200 mcg discs for the  detection 
of high-level  mupirocin resistance by disc diffusion, whereas the British Society 
27 
 
for Antimicrobial Chemotherapy (BSAC) now recommended using 20 mg discs. 
EUCAST clinical thresholds for S. aureus are 1 mg/L for susceptible and >256 
mg/L for resistant, placing the susceptible threshold at the epidemiological cut-off 
value (ECOFF). Isolates with MICs above the wild type (ECOFF 1 mg/L) but 
without a recognized resistance mechanism (MIC -4 mg/L) will thus be reported 
intermediate. Tilldate, no clinical data was found on the clinical relevance of S. 
aureus strains with these MIC levels (>1 and 4 mg/L) .65 
 
 MIC susceptibility thresholds of BSAC coincides with EUCAST 
thresholds, but disc diffusion cut-offs differ because of the 20 mg mupirocin discs 
used, rather than the 200 mcg discs recommended by EUCAST. 
  
           Genotypic techniques, i.e. mupA PCR, for identifying high level resistant 
isolates should be interpreted with utmost care, because genotypic and phenotypic 
results may vary. The mup-A positive isolates may be susceptible to mupirocin 
and high-level resistant may be mupA negative66. 
Organization Method 
Thresholds and interpretation 
Susceptible Intermediate Resistant 
CLSI 
Disc diffusion 
Tablet: 200 mcg 
 
Broth 
microdilution 
Single well: 256 
mg 
Any zone - no 
high-level 
resistance 
 
No growth - no 
high-level 
resistance 
 
No zone - 
high-level 
Resistance 
 
Growth - high-
level 
Resistance 
EUCAST 
Disc diffusion 
Tablet: 200 µg 
 
MIC 
30mm 
 
 
≤1 mg/L 
18-29mm 
 
 
2-256 mg/L 
<18mm 
 
 
>256 mg/L 
BSAC 
Disc diffusion 
Tablet: 20 mg 
 
MIC 
≥27mm 
 
 
≤1 mg/L 
7-26mm 
 
 
2-256 mg/L 
≤6mm 
 
 
>256 mg/L 
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CoNS 
 Coagulase-negative staphylococci (CoNS) was considered to be one of the 
harmless skin commensal before 1970s; however, currently it was recognized as 
an importantcause of human infections. It has been recognized as major 
nosocomial pathogens in the context of prosthetic and indwelling device-related 
infections. CoNS are also isolated most frequently in clinical microbiology 
laboratories 63. More importantly, CoNS often serve as reservoirs of antimicrobial 
resistance determinants since they usually have a high prevalence of multidrug 
resistance. Therefore, it is necessary to characterize and distinguish S. aureus 
strains and CoNS64.   
 
STREPTOCOCCUS 
 BHS was the second most common etiological agent to be isolated after 
Staphylococci from   cases of pyoderma. S. pyogenes is the only species under 
Lancefield group A Streptococcus and is the commonest cause of Streptococcal 
pyoderma. It causes a variety of suppurative infections and it can also trigger post 
infectious non-suppurative complications such as acute rheumatic fever and acute 
glomerulonephritis. 
 
 Skin damage, although minor is necessary for the development of 
Streptococcal pyoderma.The organisms first colonize and multiply in the normal 
skin before invasion through minor breaks in the epithelium and the development 
of lesions.  
 
GAS 
 GAS skin infections are often attributable to M types 49, 52, 57, and 59-61. 
They usually spread by transfer of organisms from an infected person or carrier 
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through close personal contact. Finger nails and the perianal region harbor GAS 
and play an important role in disseminating impetigo. However, in epidemics, 
fomites play animportant role in transmitting the disease. 
 
 Although serotypes causing impetigo may colonize the throat, spread is 
from skin to Skin and not via the respiratory tract.Streptococci of the same strain 
are recovered from the respiratory tract of approximately 30% of children with 
skin lesions but there is no clinical evidence of Streptococcal pharyngitis, and 
colonization occurs after the skin has become infected. The sequence of spread in 
a given patient was from normal skin to lesions and eventually to the respiratory 
tract. 
 
 The pathogenesis of S. pyogenes infection differs from S. aureus in many 
ways. Streptococcus pyogenes will not survive for prolonged period of time on 
intact normal skin.78 The resident flora does not appear to be an important first 
line of defense, since disinfecting the skin surface does not increase the survival 
of S. pyogenes on intact skin.  
 
 Colonization of skin and subsequent infections develop quickly if the 
stratum corneum barrier was disrupted. 79 
 
 Inoculation of S. pyogenes onto superficially scarificated skin results in an 
infection, but when the same inoculums was applied to intact skin, it dies off 
quickly. 78 It appears that serum provides enough nutrients for the growth of 
S.pyogenes and subsequent infection. Because S. pyogenes can penetrate the 
dermis and make its way into lymphatics and dermal vessels, systemic signs such 
as fever and regional lymphadenopathy will frequently develop early in the course 
of infection. 79 
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 Infections due to S. pyogenes most commonly occurs in the lower 
extremitiesand more common in children than in adults. This incidence probably 
reflects more frequenttrauma and minor cuts and abrasions, coupled with close 
contact from playing. Inpatients withEB, denuded skin and the abundance of 
serum facilitate infection due to S. pyogenes. 7 
 
  
Virulence factors Biological functions 
Cell wall associated polymers and 
proteins 
Capsule  
 
 
 
Prevents phagocytosis 
 
Teichoic acid  
 
Binds to epithelial cells 
M protein Adhesin and antiphagocytic; inactivates 
C3b—an important complement factor 
responsible for phagocytosis. 
Strains that are rich in M protein are 
resistant to phagocytosis and intracellular 
killing by PMNs. 
Interferes with opsonization via the 
alternative complement pathway 
F protein Mediates attachment to epithelial cells 
Enzymes  
Streptokinase  Breaks down the fibrin barrier around the 
infected site, thereby facilitating spread of 
the infection 
Deoxyribonucleases Depolymerizes 
free DNA present in the pus 
 
Depolymerizes free DNA present in the 
pus 
Hyaluronidase Hydrolyzes hyaluronic acids in the matrix 
of the connective tissues 
31 
 
 
 
ENTEROCOCCUS 
 Enterococcus faecalis is a rising cause for most of the nosocomial 
infections especially secondary skin and soft tissue infections (AgudeloHiguita 
and Huycke, 2014).  
 
 According to previous study, incidence of Enterococcal skin infections was 
8.6 per 1000 admissions in New Delhi and among them E. faecalis was 3.4 per 
1000 admissions and E. faecium was 4.8 per 1,000 admissions (Rajkumari et al., 
2014). The increased incidence leads to increased antimicrobial resistance also. 
Enterococci has an intrinsic resistance to several antibiotics (Patel et al., 2013).  
Hence Vancomycin which is often given for severe infections also leads to rising 
vancomycin resistance (Brandl et al., 2008; Humphreys, 2014). 
 
VRE 
 Vancomycin resistance among clinical Enterococcus strains developed in 
the past decade. Failure to adhere to strict infection control practices to prevent 
the spread of these pathogens, was responsible for the development of the 
resistance. It was suggested that the use of Extended-spectrum Cephalosporins 
Toxins  
Streptococcal pyrogenic 
exotoxins (SPEs) 
 
Dissolves the clot, thrombi, and emboli; 
thereby facilitates spread of the bacteria in 
tissues 
 
Streptolysin O and Streptolysin S Lyse erythrocytes, leukocytes, and 
platelets; and stimulate production of 
lysosomal enzymes 
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and drugs with potent activity against anaerobic bacteria plays a role in the spread 
of VRE, as they promote infection and colonization with these organisms.91 
 
 Treatment of Enterococcal infections usually requires a bactericidal 
combination of antibiotics which includes a cell wall-inhibitory agent to which the  
Enterococcus is susceptible and an aminoglycoside to which the Enterococcus 
does not exhibit high-level resistance. The combination commonly used includes 
PenicillinG/Ampicillin along with Gentamicin. Vancomycin was the 
recommended drug of Choice, only in cases of significant Penicillin allergy or in 
treatment of Ampicillin and Penicillin resistant strains. 92.Linezolid and 
Quinupristin/ Dalfopristin are approved therapeutic options for VRE on the basis 
of in vitro susceptibility and clinical efficacy from multicentre, pharmaceutical 
company sponsored clinical trials. 93 
 
MANAGEMENT OF PYODERMA 
DIAGNOSIS 
 Diagnosis was usually based on clinical appearance and location of lesion. 
Patients history of travel, bite history, underlying disease status, and lifestyle also 
helpsin the diagnosis. Confirmation of diagnosis was obtained by laboratory 
investigations. 7 
 
TREATMENT 
 Primary pyodermas of mild to moderate severity can be treated with local 
measures, topical anti-infective therapy, oral antibiotics, or by a combination of 
these methods.7,84Topical therapy is generally the preferred mode of antibiotic 
administration in the management for reasons of convenience and ease of 
application. 
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 Systemic therapy may be necessary only if the lesions are generalized, 
regional lymph nodes are involved, fever and / or if the lesions are deep asin the 
case of erysipelas, deep folliculitis, cellulitis and carbuncle. 84  
 
 Extensive infections have to be vigorously treated with parenteral 
antibiotics in adequate dosage. Parenteral treatment is always recommended in the 
immunocompromised host. 
 
TOPICAL THERAPY 
 Sisomicin and mupirocin79 are used in the topical management of 
pyodermas. 
 Sisomicin cream 0.1% twice a day, or mupirocin ointment 2% thrice a day 
is the treatment of choice. Both are effective and safe, however sisomicin therapy 
results in faster and greater relief of signs and symptoms. 84 
 
 Efficacy of sisomicin has been documented in the management of 
superficial infections of skin and skin structures. In vitro efficacy of sisomicin 
against a wide range of Gram positive and Gram negative clinical isolates, 
including Gentamicin resistant Ps. aeruginosa has been well established.  79,84 
 
 Topical Sodium Fusidate cream also has shown excellent results in the 
group of impetigo, Bockhart impetigo, and furunculosis, better than topical 
Gentamicin and equal to systemic Erythromycin. . 85 
 
SYSTEMIC THERAPY 
 There is no hard and fast rule for use of systemic antibiotic, but it is based 
on few principles.  
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 Systemic antibiotics are needed, if infection is wide spread or severe or   
accompanied by lymphadenopathy or if there is a reason to suscept a 
nephritogenic streptococcus or if other children are exposed to infection of if there 
is doubt whether topical medication is carried out properly, or if associated with 
systemic signs. (that is fever, malaise)32. Multiple lesions on the face and body are 
treated more aggressively with an oral antibiotic. 88 
 
 For most uncomplicated skin and skin structure infection, empheric 
antibiotic therapy is directed against most likely pathogen, Staphylococcus aureus 
and Streptococcus pyogenes. Because of their broad-spectrum coverage, clinical 
efficacy, favorable tolerability, and safety profiles, oral β-lactam antibiotics 
(penicillin, cephalosporins) are one of the mostwidely used class of antibiotics for 
uncomplicated skin infection. Due to increasing S. aureus infections, penicillinase 
resistant penicillin’s and β-lactam / β-lactamase inhibitors (e.g. Dicloxacillin and 
amoxicillin / clavulanate) are also appropriate options89. Cefdinir a third-
generation cephalosporin is safe and effective for treating skin infection with S. 
aureus, Streptococcus pyogenes and gram-negative pathogen. In addition to 
traditional antibiotics like β-lactams macrolides and clindamycin, newer broad-
spectrum antibiotics to treat resistant pathogens are available like streptogramins, 
oxazolidinediones and third generation fluroquinolones like moxifloxacin and 
gatifloxacin. 88 
 
Control measures 
 Pyoderma is best prevented by attention to adequate personal hygiene. 25 
Isolation of patients with open draining Staphylococcal infections, strict hand 
washing procedures, good nursery techniques, and careful handling of patients are 
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important in the reduction of transmission of infection and thus serve as good 
control measures.7 
 
 A correct antimicrobial policy and the avoidance of inappropriate 
antimicrobial usage are mandatory to reduce the spread of MRSA in the 
community.50  
 
Morbidity 
 Inspite of the fact that Pyoderma was easily treatable, it was known for its 
chronicity, recurrence and various other complications. 7 
 
 S.aureus causing pyoderma, if left untreated can invade the blood 
stream,producing bacteremia, metastatic infections such as osteomyelitis, septic 
arthritis, brain abscess, pneumonitis and an acute infective endocarditis. 7 
Staphylococci from boils and carbuncles in food handlers can be transmitted to 
food and can cause food poisoning. 90 
 Scarlet fever, urticaria, and erythema multiforme may follow Streptococcal  
impetigo. Invasive complications of Streptococcal pyoderma include 
lymphangitis, lymphadenitis and bacteremia. The most important sequelae of 
Streptococcal skin infections were post streptococcal glomerulonephritis. The 
pyoderma associated nephritogenic strains belongs to the serotypes 2, 49, 42, 55, 
56, 57 and 60. The frequency of AGN after infection with a known nephritogenic 
strain was 10% to 15%.7 
 
  
 Materials and Methods 
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MATERIALS AND METHODS 
 
STUDY DESIGN: 
Place of study:  
 The Study was conducted at theInstitute of Microbiology, Madras Medical 
College in association with the Department of Dermatology, Rajiv Gandhi 
Government General Hospital, Chennai. 
 
Study period: 
 The study was conducted over a period of One year from March 2017 to 
February 2018. 
 
Study type: 
 A hospital based prospective Cross-sectional study 
 
Sample size:    
 The sample size of my study was 200 cases of pyoderma 
 
Study population: 
 All out patients & in patients of Pyoderma attending the Departmentof 
Dermatology, Rajiv Gandhi General hospital were included in this study.   
 
Ethical consideration 
 Ethical clearance was obtained from Institutional Ethics committee and 
Informed consent was obtained from all the patients who participated in this 
study. 
37 
 
Statistical analysis 
 Statistical analyses were carried out using Statistical Packages for Social 
Sciences (SPSS) software (Version 16.0; SPSS Inc., Chicago). The proportional 
data of this cross sectional study were analyzed using Pearson’s Chi Square 
analysis test. 
 
Inclusion Criteria: 
 Patient aged more than 18 years. 
 Inpatients/Outpatients with Primary and Secondary Pyoderma attended 
Dermatology Department of RGGGH, Chennai. 
  Patients with Pustule, Papulovesicles, Bullae, Ulcer, Inflammatory plaques 
with oozing, crusting signifying bacterial skin infection. 
 
Exclusion Criteria: 
 Those who are on antibiotic therapy & denied consent will be excluded.  
 
Sample collection:    
Sample was taken before the start of treatment, samples(pus) for culture was 
collected from the base of the lesion using sterile swab. 
 
 The surrounding area of the lesion was cleaned with 70% alcohol followed 
by 10% povidone iodine solution before collecting the samples.Prior to the pus 
collection,iodine was removed from the area with alcohol  
 
 The intact pustule was ruptured with sterile needle and then  the sample 
was taken with sterile cotton swab stick.  
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 The debris was removed as far as possible in open wounds and then the 
lesion was  rinsed thoroughly with sterile saline prior to sample collection.  
 
 In crusted lesions, the crusts were partly lifted and then the sample was 
taken from underneath. 
 
 All the samples were collected aseptically with two sterile cotton swabs for 
each sample from the lesion and kept in a sterile tube after proper labeling with 
name, age, gender, OP/IP number and date. Then the swabs were immediately 
transported to the microbiology laboratory without any delay. 
 
Sample processing 
 In the laboratory the samples were processed immediately. Gram staining 
was done using one swab and aerobic culture using the other swab. 
 
Gram staining 
 One swab is used for gram staining.  A sterile glass slide was cleaned and 
exposed to Bunsen flame and allowed to cool and then a direct smear was made 
over the slide. The smear was allowed to air dry and then it was heat fixed by 
passing the under surface of the slide over the flame.  
 
 The fixed smear was covered with methyl violet stain for 60 seconds. 
Rapidly wash off the stain with clean water. After tip off all the water, cover the 
smear with Grams iodine for 60 seconds. Wash off the iodine with clean waterand 
decolorize rapidly (few seconds) with acetone. Wash immediately with clean 
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waterand Cover the smear with carbolfuchsin stain for 60 seconds. Wash off the 
stain with clean water, Wipe the back of the slide clean, and place it in a draining 
rack for the smear to air-dry. The smear was examined microscopically, first with 
the 40objectives to check the staining and to see the distribution of material, and 
then with the oil immersion objective to report the bacteria and cells. 
 
CULTURE 
The Second swab was inoculated onto the following media: 
 Nutrient agar 
 Blood agar 
 MacConkey agar 
 
 
 The inoculated media were incubated aerobically at 37°C for 24 hours. In 
 case ofno growth after 24 hours, the plates were further incubated for another 24  
hours. 
 
3) Identification of the isolates 
 Organisms grown were then identified on the basis of their colony 
characteristics and biochemical reactions as per the standard protocol. 
 
BIOCHEMICAL TESTS 
1. Catalase test 
2. Coagulase test 
3. Oxidase test  
4. Bacitracin susceptibility test 
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5. Bile esculin agar 
6. Growth at 10 &40oC for enterococci 
7. Hanging drop 
8. Nitrate reduction test 
9. Hugh and Leifson’s oxidation fermentation test 
10. Indole test 
11. Methyl red and Voges-Proskauer test 
12. Citrate utilization test 
13. Urease test 
14. Triple sugar iron agar test 
15. Sugar fermentation test   
16. Moeller’s decarboxylase test 
17. PYR test. 
 
Catalase test 
Principle 
 This test is used to differentiate the bacteria that produce the enzyme 
catalase, which acts as a catalyst in the breakdown of hydrogen peroxide to 
oxygen and water. 
 
Procedure 
 With an inoculating needle or a wooden applicator stick, growth from the 
center of a Colony was transferred  to the surface of a glass slide.One drop of 3% 
hydrogen peroxide  is added and observed for bubble formation.  
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Interpretation 
 The rapid and sustained appearance of bubbles or effervescence constitutes 
a positive test. Because some bacteria possess enzymes other than catalase that 
can decompose hydrogen peroxide, a few tiny bubbles forming after 20–30 
seconds is not considered a positive test. In addition, catalase is present in red 
blood cells; so care must be taken to avoid carryover of red blood cells.  
 
Coagulase test 
 The coagulase test is used to identify Staphylococcus aureus and 
differentiate it from most other species of Staphylococci.  Coagulase is present in 
two forms, bound and free, each having different properties that require the use of 
separate testing procedures. 
 
Procedure 
Slide test (bound coagulase):  
 Two drops of saline were placed in two circles drawn on a glass slide with 
a wax pencil. The colony material from the organism to be identified is gently 
emulsified in saline in each of the circles. A drop of plasma is placed in the 
suspension in one of the circles and mixed with a wooden applicator stick. 
Another drop of saline was placed in the other circle as a control, the slide was 
rocked back and forth and observed for agglutination of the test suspension. 
 
Tube test (free coagulase) 
 A small amount of the colony growth of the organism was emulsified in a 
tube containing 0.5mL of plasma. The tube is incubated at 35°C for 4 hours and 
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observed for clot formation by gently tilting the tube. If no clot is observed at that 
time, the tube is reincubated at room temperature and read again after 18 hours. 
 
Interpretation 
Slide test:  
 A positive reaction was detected within 10–15 seconds of mixing the 
plasma with the suspension by the formation of a white precipitate and 
agglutination of the organisms in the suspension. The test was considered negative 
if no agglutination was observed after 2 minutes.  
Tube test:  
 The tube coagulase test was considered positive if any degree of clotting is 
noted. The tube should be gently tilted and not agitated, because this may disrupt 
partially formed clotted material. Fibrinolysins produced by the organism may 
also dissolve the clot soon after formation. Tube tests that are negative after 4 
hours should be incubated at room temperature overnight and read after 18 hours. 
 
OXIDASE TEST  
Principle:  
 The cytochrome oxidase test uses certain reagent dyes, such as p-
phenylenediamine dihydrochloride, that substitute for oxygen as artificial electron 
acceptors. In the reduced state, the dye is colorless; however,in the presence of 
cytochrome oxidase and atmospheric oxygen, p-phenylenediamine is 
oxidized,forming indophenol blue. 
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Procedure:  
 Filter paper soaked with oxidase reagent (1% tetramethyl-P-Phenylene 
diamine dihydrochloride) was placed in a Petri dish and the colony to be tested 
was smeared on it using a sterile glass rod.  
 
Interpretation 
 Bacterial colonies having cytochrome oxidase activity develop a deep blue 
color at the inoculation site within 10 seconds. Any organism producing a blue 
color in 10- to 60-secondperiod was considered negative, and it can be concluded 
that it does not belong to the familyEnterobacteriaceae. 
 
NITRATE REDUCTION TEST  
Principle:  
 This test demonstrates the presence of nitrate reductase enzyme which 
reduces nitrate to nitrite.  
 
Reagent: 
Reagent A 
 α-Naphthylamine           5 g 
 Acetic acid (5 N), 30%    1 L 
Reagent B 
 Sulfanilic acid      8 g 
 Acetic acid (5 N), 30%  1 L 
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Procedure    
 With a loopful of the test organism isolated wasinoculated in the nitrate 
medium and incubated at 35°C for 18–24 hours. At the end of incubation, 1 mL 
each of reagents A and B was added to the test medium, in that order 
 
Interpretation:  
 The development of a red color within 30 seconds after adding the test 
reagents indicates the presence of nitrites and represents a positive reaction for 
nitrate reduction. 
 
INDOLE PRODUCTION TEST  
Principle:  
 This test demonstrates the presence of enzyme tryptophanase, that degrades 
tryptophan to indole. 
 
Procedure:  
 Kovacs reagent ingredients  
 P-Dimethylaminobenzaldehyde-10g  
 Isoamyl alcohol – 150ml 
 Concentrated hydrochloric acid-50ml 
 
 The test organism was inoculated into peptone water and incubated for 24 
hours and then 15 drops of reagent was added along the inner wall of the tube. 
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Interpretation:  
 The development of a bright fuchsia red color at the interface of the 
reagent and the broth within seconds after adding the reagent was indicative of the 
presence of indole and interpreted as a positive test. 
 
UREASE TEST  
Principle:  
 This test demonstrates the presence of urease enzyme which splits urea to  
ammonia and CO2.  
 
Procedure: 
 Test organism was inoculated on to slope of Christensen's urease medium 
and incubated at 37°C for 24 to 48 hours.  
 
Interpretation:  
       Organisms that hydrolyze urea rapidly shows positive reactions within 1 or 2 
hours; less active species may require 3 or more days. Development of pink color 
in the slope was interpreted as a positive test.  
 
CITRATE TEST  
Principle:  
 This test demonstrates the ability of an organism to use citrate as sole 
source of carbon.  
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Procedure: 
 The test organism was inoculated on to slope of Simmon's citrate medium 
and incubated at 37°C for 24 to 48 hour. 
 
Interpretation:  
 Development of deep blue colour in the medium was interpreted as a 
positive test.If there is visible colony growth along the inoculation streak line it 
was considered as a positive test without development of blue color. 
 
METHYL RED TEST 
Principle: 
 This test detects the production of acid during the fermentation of glucose 
and maintenance of pH below 4.5.  
 
Procedure:  
 The test organism was inoculated in to glucose phosphate broth and 
incubated at 37 °C for 48 to 72 hours. Few drops of 0.04% solution of methyl red 
was added to the broth. 
 
Interpretation:  
 Development of red colour in the surface of the medium was interpreted as 
a positive test.  
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VOGES-PROSKAUER TEST 
Principle: 
 This test detects the production of acetyl methyl carbinol from pyruvic acid 
as an intermediate stage in its conversion to 2:3 butylene glycol. In presence of 
alkali and atmospheric oxygen, small amount of acetyl methyl carbinol is oxidized 
to diacetyl which reacts with peptone in the broth.  
 
Procedure:  
 The test organism was inoculated into glucose phosphate broth and 
incubated at 37°C for 48 to 72 hours. Aliquot 1 mL of broth to a clean test tube 
and add 0.6 mL of 5% α-naphthol followed by 0.2 ml of 40% KOH. 
 
Interpretation: 
 The development of a red color 15 minutes or more after addition of the 
reagents was considered as a positive test. 
 
TRIPLE SUGAR IRON AGAR TEST  
 It is a composite solid agar medium in tube having a butt and a slant. Its 
constituents include: 
 
 Three sugars-glucose, sucrose and lactose in the ratio of 1:10:10 parts. 
 Phenol red as an indicator of acid production. 
 Ferric salt as an indicator of hydrogen sulfide (H2S) production. 
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Procedure 
 Medium was inoculated with a pure bacterial culture by a straight wire 
pierced deep in the butt (stab culture) and then doing a stroke culture on the slant 
area. the tube is incubated at37°C for 18- 24 hours. Under incubation or over 
incubation may lead to false interpretation of result. 
 
Interpretation:  
Alkaline slant / No change in butt           non fermenter 
(K / No change) 
Alkaline slant / Acid butt (K/A)  glucose only fermenter  
Acid slant / Acid butt (A/A) glucose, sucrose and / lactose fermenter  
 
 A black precipitate in the butt indicates production of ferrous sulphide and 
H2S gas. Bubbles or cracks in the tube indicate the production of CO2 or H2. 
 
SUGAR FERMENTATION TEST  
 It detects the ability of an organism to ferment a specific carbohydrate 
(sugar) incorporated in a medium producing acid with/without gas. 
 
Procedure: 
Sugar fermentation medium  
Peptone   - 15g 
Phenol red  - 10ml 
Sugar    - 20g 
Water   - 10ml 
 Each tube was inoculated with 1 drop of 18-24 hours broth culture and 
incubated at 35°-37°C for up to 7 days in ambient air. The tubes are examined for 
acid and gas production. 
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Interpretation: 
         Positive test is indicated by growth and change of colour to yellow. Gas  
production is indicated by the presence of bubbles in the inverted Durham tube. 
 
OXIDATION –FERMENTATION TEST (Hugh-Leifson's method)  
 This test is used to differentiate microorganisms based on their ability to 
oxidize or ferment specific carbohydrates. Hugh-Leifson's basal medium is 
prepared and the carbohydrate to be added is sterilized separately and added to 
give a final concentration of 1 %.  
 
Procedure 
 Two tubes are required for the OF test, each tube  inoculated with the 
unknown organism, using a straight needle, stabbing the medium three to four 
times halfway to the bottom of the tube. One tube of each pair was covered with a 
1-cm layer of sterile mineral oil or melted paraffin, leaving the other tube in air. 
Both tubes are incubated in ambient air for up to 7 days.  
 
Interpretation: 
 Fermenting organisms produce an acid reaction throughout the medium in 
covered (anaerobic) as well as the open (aerobic) tube. Oxidizing organisms 
produce an acid reaction only in the open tube.  
 
 Organisms that cannot breakdown the carbohydrate aerobically or 
anaerobically produce an alkaline reaction in the open tube and no change in 
covered tube. 
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Moeller’s Decarboxylase Tests 
 This test was used to differentiate decarboxylase producing 
Enterobacteriaceae from other gram negative rods. 
 
Procedure  
 The tubes were inoculated with 1 drop of an 18- to 24-hour brain-heart 
infusion broth cultureand 4-mm layer of sterile mineral oil was added to each 
tube. Incubated at35°-37°C in ambient air.  
 
Result : 
 Positive: Alkaline (purple) color change compared with the control tube 
 
PYR Test 
Principle 
 This test was now a standard assay for the presumptive identification of 
both group A β-hemolytic Streptococci and Enterococci. 
 
Procedure 
 Two to three morphologically similar colonies are picked up with a sterile 
bacteriologic loop and emulsified  in the small volume of PYR broth. The tube 
was incubated at 35-37°C for 4 hours. One drop of the PYR reagent was added 
and observed for color change. (The reaction should be read and recorded 1 
minute after the addition of reagent.) 
 
Interpretation 
 The development of a deep cherry red color within a minute of addition of 
the reagent is interpreted as Positive.A yellow or orange color was interpreted as 
Negative. 
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IDENTIFICATION TESTS: 
Staphylococcus aureus- [Mackey] 
 Morphology in culture Medias: 
 Nutrient agar- as smooth, low convex, glistening, densely opaque and of 
butyrous consistency30. The pigment formation in nutrient agar when kept in room 
temperature inaerobic atmosphere ranges from cream colour to golden yellow due 
topresence of carotenoids. 
 
 Blood agar- as white opaque colonies surrounded by a zone of  
β-hemolysis31.On MacConkey agar(MAC)-Small opaque colonies and acquires 
the colour of the indicator and appear as pink. 
 Gram staining showed Gram positive cocci in clusters. 
 Colonies were subjected to the following biochemical  tests. 
 
S.NO TESTS RESULTS 
1. Catalase test Positive 
2. Coagulase test( Slide and Tube method) Positive 
3. Urease test Urea hydrolysed 
4. Voges-Proskauer Acetoin produced 
5. Hugh-Leifson’s Oxidation Fermentation test Fermentative pattern 
6. Mannitol fermentation test Fermented with gas production 
 
Enterococcus faecalis- [Mackey] 
 Gram staining showed Gram positive oval cocci arranged in pairs and short 
chains 
 Colony morphology  
On 5% Blood Agar Plate(BAP) - Tiny Translucent  non-haemolytic colonies  
52 
 
On MacConkey agar(MAC)-Small Magenta coloured colonies 
 Colonies were subjected to the following biochemical  tests. 
S.NO TESTS RESULTS 
1. Catalase test Negative 
2. Heat tolerance test at 45ºC Positive 
3. Voges-Proskauer Acetoin produced 
4. Bile esculin hydrolysis Positive 
5. Sorbitol Fermented 
6. Arabinose Fermentation Test Not fermented 
 
Klebsiella species-[Mackey] 
 Colony  morphology  
 On MacConkey agar(MAC)-Large mucoid Lactose fermenting colonies  
 On 5% Blood Agar Plate(BAP)-Large greyish-white mucoid colonies 
 Gram staining showed Short plump Gram negative bacilli 
 Motility test by Hanging Drop method- Non-Motile 
 Colonies were subjected to the following biochemical tests.[Mackey 
 
S.NO TESTS Klebsiella pneumonia Klebsiellaoxytoca 
1. Catalase Positive Positive 
2. Oxidase Negative Negative 
3 Nitrate Reduction test Positive Positive 
4. Hugh-Leifson’s Oxidation Fermentation test Fermentative Fermentative 
5. Indole test Indole not produced Indole produced 
6. Methyl Red test(MR) Voges-Proskauer test(VP) 
MR:Negative 
VP: acetoin 
produced(Positive) 
MR: Negative 
VP: acetoin 
produced(Positive) 
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7. Simmon’sCitrate Utilization test Citrate utilized Citrate utilized 
8. Christensen’s Urease test Urea hydrolyzed Urea hydrolyzed 
9. Triple Sugar Iron agar test (TSI) 
Acid butt/acid slant 
with gas production 
and no H2S 
production 
Acid butt/acid slant 
with gas production 
and no H2S 
production 
10. Lysine Decarboxylation test Decarboxylated Decarboxylated 
 
E.coli 
 Colony  morphology  
On MacConkey agar(MAC)- Smooth, glossy Lactose fermenting colonies  
 Gram staining showed  Gram negative bacilli 
 Motility test by Hanging Drop method-Motile 
 Colonies were subjected to the following biochemical  tests.[Mackey 
S.NO TESTS RESULTS 
1. Catalase Positive 
2. Oxidase Negative 
3 Nitrate Reduction test Positive 
4. Hugh-Leifson’s Oxidation Fermentation test Fermentative 
5. Indole test Indole  produced 
6. 
Methyl Red test(MR) MR: Positive  
Voges-Proskauer test(VP) VP: negative  
7. Simmon’sCitrate Utilization test Citrate not utilized 
8. Christensen’s Urease test Urea not hydrolyzed 
9. Triple Sugar Iron agar test(TSI) Acid butt/acid slant with gas production and no H2S production 
10. Lysine Decarboxylation test Decarboxylated 
11. Mannitol motility medium Fermented  and motile 
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Proteus spp 
1.Colony  morphology 
 On MacConkey agar(MAC)- Lactose non- fermenting colonies  
 On 5% Blood Agar Plate(BAP)-greyish white colonies with swarming 
2.Gram staining showed Gram negative bacilli 
3.Motility test by Hanging Drop method-Motile 
4. Colonies were subjected to the following Identification tests. [Mackey 
S.NO TESTS Proteus mirabilis Proteus vulgaris 
1. Catalase Positive Positive 
2. Oxidase Negative Negative 
3 Phenylalanine deaminase test Positive Positive 
4. Hugh-Leifson’s Oxidation Fermentation test Oxidative Oxidative 
5. Indole test Not produced Indole produced 
7. Simmon’sCitrate Utilization test Citrate utilized Citrate utilized 
8. Christensen’s Urease test Urea hydrolyzed Urea hydrolyzed 
9. Triple Sugar Iron agar test(TSI) 
Acid  butt/alkaline  
slant with H2S 
production 
Acid  
butt/alkaline  
slant with H2S 
production 
10. Maltose Not fermented Fermented 
11. Arginine Dihydrolase test Negative Negative 
12. Lysine decarboxylation Negative Negative 
13. Ornithine decarboxylation Positive Negative 
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Pseudomonas aeruginosa. [Mackey 
 Colony  morphology – 
On MacConkey agar(MAC)-Large Spreading Lactose non- fermenting 
colonies  
On Nutrient Agar plate-Irregular colonies with metallic sheen and blue 
green diffusible pigment 
 Gram staining showed Gram negative  bacilli 
 Motility test by Hanging Drop method-Motile 
 Colonies were subjected to the following Identification tests.[Mackey 
S.NO TESTS RESULTS 
1. Catalase Positive 
2. Oxidase Positive 
3 Nitrate Reduction test Positive 
4. Hugh-Leifson’s Oxidation Fermentation test Oxidative 
5. Indole test Not produced 
7. Simmon’s Citrate Utilization test Citrateutilized 
8. Christensen’s Urease test Urea not hydrolysed 
9. Triple Sugar Iron agar test(TSI) 
Alkaline  butt/alkaline  
slant without gas or H2S 
production 
10. Arginine Dihydrolase test Positive 
12. Growth at 42ºC Positive 
 
Acinetobacter baumannii 
 Colony  morphology 
On MacConkey agar(MAC)-Large Lactose non- fermenting pale pink 
colonies  
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 Gram staining showed Gram negative cocco- bacilli 
 Motility test by Hanging Drop method-Non-Motile 
 Colonies were subjected to the following Identification tests.[Mackey 
S.NO TESTS RESULTS 
1. Catalase Positive 
2. Oxidase Negative 
3 Nitrate Reduction test Negative 
4. Hugh-Leifson’s Oxidation Fermentation test Oxidative 
5. Indole test Not produced 
6. Simmon’sCitrate Utilization test Citrate utilized 
7. Christensen’s Urease test Urea not hydrolyzed 
8. Triple Sugar Iron agar test(TSI) Alkaline  butt/alkaline  slant 
9. Growth at 42ºC Positive 
10. 10% OF Lactose Utilization test Positive 
 
ANTIBIOTIC SENSITIVITY TESTING   
 The colonies were identified as Staphylococcus aureus, beta hemolytic 
Streptococci, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella 
pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Proteus vulgaris, E. coli, and 
Acinetobacter baumannii by gram staining and other biochemical reactions and 
antibiotic sensitivity testing was performed. 
 
 Antimicrobial susceptibility testing to be done for the isolates on Mueller 
HintonAgar by Kirby-Bauer Disc Diffusion method as per CLSI guidelines. For 
Streptococci and Enterococci sensitivity was performed on 5% Sheep blood agar.       
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DISC DIFUSSION METHOD  
 With a sterile loop, touch the tops of four or five similar-appearing, well-
isolated colonies of the test organism from an overnight growth on primary agar 
plate and are suspended in 0.5ml of sterile saline.  
 
 The turbidity was matched with 0.5 Mc Farland turbidity standards.  
 
 A fresh sterile cotton tipped swab was dipped into the suspension and the 
excess of inoculum was removed by pressing it against the sides of the tube.  
 
 The dried surface of a Mueller–Hinton agar plate was  brought to room 
temperature and inoculated  by streaking the swab three times over the entire agar 
surface by rotating the plate approximately 60 degrees each time for even 
distribution of the inoculum. The rim of the agar was swabbed finally and the lid 
of the dish was replaced. Before adding the antibiotic disks allow the surface of 
the agar to dry for at least 3–5 minutes but no longer than 15 minutes. 
 
 The antibiotic discs were placed on the plate using sterile forceps so that 
even contact is ensured and incubated aerobically at 37°C.  
 
 After 18 to 24 hours of incubation the diameter of the clear zone around the 
disc was measured under transmitted light with measuring scale and results were 
interpreted as susceptible, intermediate or resistant as per the CLSI criteria. 
 
 The antibiotic disc was obtained from HI MediaLaboratories. The 
concentration of the antibiotic disc wasused as per CLSI guidelines. 
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 The diameter of each zone (including the diameter of the disc) of inhibition  
was measured and recorded in millimeters and the result was then compared with 
the zone size interpretative chart according to CLSI guidelines. 
 
 The quality control for antimicrobial susceptibility testing was done with  
standard strains of   S. aureus (ATCC 25923), E. coli (ATCC 25922) and Ps. 
aeruginosa (ATCC 27853) 
 
Zone Diameter Interpretive Standards for Staphylococcus species 
Antimicrobial 
Agent 
Disc 
content 
Zone Diameter Interpretive Criteria 
(nearest whole mm) 
Sensitive Intermediate Resistant 
Penicillin 10 units ≥ 29 - ≤ 28 
Gentamycin 10 µg ≥15 13-14 ≤12 
Erythromycin 15 µg ≥23 14-22 ≤13 
Tetracycline 30 µg ≥19 15-18 ≤ 14 
Ciprofloxacin 5 µg ≥21 16-20 ≤ 15 
Trimethoprim/ 
Sulfamethoxazole 
1.25/23.75 
µg ≥16 11-15 ≤ 10 
Chloramphenicol 30 µg ≥18 13-17 ≤12 
Linezolid 30 µg ≥21 - ≤ 20 
 
Zone Diameter Interpretive Standards for Enterobacteriaceae[clsi] 
Antimicrobial 
Agent 
Disc content 
 
Zone Diameter Interpretive Criteria 
(nearest whole mm) 
Sensitive Intermediate Resistant 
Amikacin 30 µg ≥ 17 15-16 ≤ 14 
Gentamicin 10 µg ≥15 13-14 ≤ 12 
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Ciprofloxacin 5 µg ≥21 16-20 ≤ 15 
Trimethoprim/ 
Sulfamethoxazole 
1.25/ 
23.75 µg ≥16 11-15 ≤ 10 
Tetracycline 30 µg ≥15 12-14 ≤ 11 
Cefotaxime 
 
30 µg 
 ≥26 23-25 ≤ 22 
Ceftazidime 30 µg ≥21 18-20 ≤ 17 
Piperacillin-
Tazobactam 
100/ 
10 µg ≥21 18-20 ≤ 17 
Imipenem 10 µg ≥23 20-22 ≤ 19 
 
Zone Diameter Interpretive Standards for Gram Negative Non-Fermenter 
Bacteria 
Antimicrobial 
Agent 
Disc 
content 
 
Gram Negative 
Bacilli 
Zone Diameter Interpretive 
Criteria (nearest whole mm) 
Sensitive Intermediate Resistant 
Amikacin 30 µg 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumannii 
≥ 17 15-16 ≤ 14 
Gentamicin 10 µg 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumannii 
≥15 13-14 ≤ 12 
Trimethoprim/ 
Sulfamethoxazole 
1.25/ 
23.75 
µg 
Acinetobacter 
baumannii ≥16 11-15 ≤ 10 
Ciprofloxacin 5 µg 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumannii 
≥21 16-20 ≤ 15 
Ceftazidime 30 µg 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumannii 
≥18 15-17 ≤ 14 
Piperacillin-
Tazobactam 
100/ 
10 µg 
Acinetobacter 
baumannii ≥21 18-20 ≤ 17 
Pseudomonas 
aeruginosa ≥21 15-20 ≤ 14 
Imipenem 10 µg 
Pseudomonas 
aeruginosa ≥19 16-18 ≤ 15 
Acinetobacter 
baumannii ≥22 19-21 ≤ 18 
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PHENOTYPIC SCREENING  TEST FOR METHICILLIN RESISTANCE 
STAPHYLOCOCCUS AUREUS 
Detection of mec A mediated oxacillin resistance using cefoxitin: 
 Medium -MHA 
 Antimicrobial concentration -30 µg cefoxitin disk 
 Inoculum- Standard disk diffusion procedure  
 Incubating condition- 33 to 35°C; ambient air (Testing at temperatures 
above 35°C may not detect MRSA.) 
 Incubation length -  16–18 hours 
 24 hours (may be reported after 18 hours, if resistant) 
 
RESULTS 
S.aureus      CONS 
 ≤ 21 mm = mecA positive                              ≤ 24 mm = mecA positive  
  ≥ 22 mm = mecA negative                            ≥ 25 mm = mecA negative 
 
 Cefoxitin was used as a surrogate for mecA-mediated oxacillin resistance. 
Isolates that test as mecA positive should be reported as oxacillin (not cefoxitin) 
resistant; other β-lactam agents, except those with anti-MRSA activity, should be 
reported as resistant. 
 
 All the MRSA isolates were subjected to the following screening and 
confirmatory test for detection of Mupirocin resistance. 
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Detection of high level mupirocin resistance for MRSA isolates 
Disk diffusion Test method - 
 Medium- MHA 
 Antimicrobial concentration –200-µg mupirocin disk 
 Inoculum- Standard disk diffusion procedure  
 Incubating condition- 33 to 35°C; ambient air (Testing at temperatures 
above 35°C may not detect MRSA.) 
 Incubation length - 24 hours  
` 
RESULTS 
 Results Examined carefully with transmitted light for light growth within 
the zone of inhibition.  
 No zone = high-level mupirocin resistance.  
 Any zone = the absence of high-level mupirocin resistance.  
 
E-test 
 Ezy MIC™ strip was useful for quantitative determination of susceptibility 
of bacteria toantimicrobial agents. The system comprises of a predefined 
quantitative gradient which was used to determine the Minimum Inhibitory 
Concentration (MIC) in mcg/ml of different antimicrobialagents against 
microorganisms tested on appropriate agar media, following overnightincubation. 
Mupirocin Ezy MIC Strip (MUP) (0.064-1024 mcg/ml) 
 
 It was a unique MIC determination paper strip which was coated with 
Mupirocin on a single paper strip in a concentration gradient manner, capable of 
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showing MICs in the range of 0.064 mcg/ml to 1024 mcg/ml, on testing against 
the test organism 
 
Preparation of Inoculum 
  Direct colony suspension was prepared from18-24-hour old non-selective 
media agar plate in saline.  Adjust the turbidity to that of standard 0.5 McFarland 
 
Test Procedure 
 Plates with  suitable make of Mueller Hinton Agar was prepared .A sterile 
non-toxic cotton swab on a wooden applicator was dipped into the standardized 
inoculum and rotate the soaked swab firmly against the upper inside wall of the 
tube to express excess fluid.  The entire agar surface of the plate was streaked 
with the swab three times, turning the plate at 60° angle between each streaking. 
 
 Ezy MIC™ strip container was removed  from cold and keep it at room 
temperature for 15minutes before opening. One applicator was removed from the 
self sealing bag stored at room temperature. Ezy MIC™ strip was lifted by 
holding the applicator in the middle and gently press its broader sticky side on the 
centre of the strip. The strip was placed at a desired position on agar plate pre-
spread with test culture. Gently turnthe applicator clockwise with fingers to detach 
from the strip.DO NOT PRESS EZY MIC™ STRIP. Within 60 seconds, Ezy 
MIC™ strip was adsorbed and will firmly adhere to the agar surface. 
 
 Ezy MIC™ strip should not be repositioned or adjusted once placed. 
Transferthe plates to the incubator under appropriate conditions. 
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MIC Reading: 
            Read the plates only when sufficient growth was seen and read the MIC 
where the ellipse intersects the MIC scale on the strip. 
 
 For bacteriostatic drugs such Mupirocin, Chloramphenicol, Azithromycin, 
Fluconazole, and Trimethoprim/ sulphamethoxazole, read MICs at 80% inhibition 
forhomogenously sensitive strains such as QC control strains.  
 
 Isolated colonies, microcolonies and hazes appearing in the zone of 
inhibition areindicative of hetero nature of the culture having resistant 
subpopulation in it. In suchcases, consider reading for MIC determination at a 
point on the scale above which noresistant colonies are observed close to MIC 
strip (within 1-3 mm distance from thestrip). 
 
 Since Ezy MIC™ strip has continuous gradient, MIC values “in-between” 
two-fold dilutions can be obtained. Always round up these values to the next two-
fold dilution before categorization. Forexample: mupirocin showing reading of 
0.75mcg/ml should be rounded up to nextconcentration i.e. 1.0 mcg/ml. If the 
ellipse intersects the strip in between 2 dilutions, read the MIC as the value 
whichis nearest to the intersection. 
 
  When growth occurs along the entire strip, report the MIC as > the highest 
values on theMIC strip. When the inhibition ellipse is below the strip (does not 
intersect the strip), report the MIC < the lowest value on the MIC scale. 
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Ezy MIC™ Strip FEATURES AND ADVANTAGES 
Ezy MIC™ strip exhibits several advantages over existing plastic strip. 
Ezy MIC™ strip was made up of porous paper material unlike plastic non-porous 
material 
Ezy MIC™ strip has MIC values printed on both sides identically. 
 
 The antimicrobial agent was evenly distributed on either side of the Ezy 
MIC™ strip and henceit can be placed by any side on the agar surface. For Ezy 
MIC™ strips, MIC values can be read without opening the lid of the plate as most 
commonly translucent medium such as Mueller Hinton Agar is employed. 
 
 Once placed, Ezy MIC™ strip is adsorbed within 60 seconds and firmly 
adheres to the agarsurface. Unlike the plastic material, it does not form air bubbles 
underneath and hence there is no needto press the strip once placed. 
 
GENOTYPIC METHOD 
 PCR   for mup A gene 
 
Material & Methods: 
 Pure Fast® Bacterial DNA minispin purification kit [Kit contains 
Lysozyme, Lysozymedigestion buffer, Proteinase-K, Binding buffer, Wash 
Buffer-1, Wash Buffer-2, Spin columnswith collection tube and elution buffer. 
HELINI 2X ReDdye PCR Master Mix, Agarose gelelectrophoresis consumables 
and mupA and CFR Primers are from HELINI Biomolecules, Chennai, India. 
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2X Master Mix: 
 It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
MgCl2, 1μl of10mM dNTPs mix and RedDye PCR additives. 
 
Agarose gel electrophoresis: 
 Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide 
are from HELINIBiomolecules, Chennai. 
 
PCR: 
 HELINI Ready to use mupA gene Primer mix - 5μl/reaction 
 PCR Product: 460bp 
 
Bacterial DNA Purification 
 1ml of overnight culture was centrifuged at 6000rpm for 5min and the 
Supernatant was discarded. The Pellet was suspended in 0.2ml PBS, 180μl of 
Lysozyme digestion buffer and 20μl of Lysozyme [10mg/ml] was added and 
Incubated at 37C for 15min. 
 
 400μl of Binding buffer, 5μl of internal control template and 20μl of 
Proteinase K added, and mixed well by inverting several times and incubated 
at 56ºC for 15min. 
 300μl of Ethanol was added and mixed well, the entire sample was transferred 
into the PureFast® spin column and centrifuged for 1 min. Discard the flow-
through and place the column back into the same collection tube. 
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 500μl Wash buffer-1 was added to the PureFast® spin column and centrifuged 
for 30-60 seconds and discard the flow-through. Place the column back into 
the same collection tube. 
 500μl Wash buffer-2 was added to the PureFast® spin columnand Centrifuged 
for 30-60 seconds and the flow-through was discarded. Place the column back 
into the same collection tube. 
 Discard the flow-through and centrifuged for an additional 1 min. This step 
was essential toavoid residual ethanol. Transfer thePureFast® spin column 
into a fresh 1.5 ml micro-centrifuge tube. And 100μl of Elution Buffer was 
added to the center of PureFast® spin column membrane. Incubated for 1 min 
at room temperature and then centrifuged for 2 min. 
 Discard the column and store the purified DNA at -20°C. Quality and Quantity 
ofextracted DNA was checked by loading in 1% agarose gel and 5μl of 
extracted DNA wasused for PCR amplification. 
 
PCR Procedure: 
1.Reactions set up as follows; 
Components Quantity 
HELINI RedDye PCR Master mix 10μl 
HELINI Ready to use - Primer Mix 5μl 
Purified Bacterial DNA 5μl 
Total volume 20μl 
 
2. Mixed gently and spin down briefly. 
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3. Placed into PCR machine and program it as follows; 
 Initial Denaturation  : 95ºC for 5 min 
 Denaturation   : 94ºC for 30sec 
 Annealing   : 58ºC for 30sec 35 cycles 
 Extension   : 72ºC for 30sec 
 Final extension  : 72º C for 5 min 
 
Loading: 
1. Prepared 2% agarose gel. [2gm of agarose in 100ml of 1X TAE buffer] 
2. Run electrophoresis at 50V till the dye reaches three fourth distances and 
observe thebands in UV Transilluminator 
 
Agarose gel electrophoresis: 
 Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer and 
melted using microoven) 
 
 When the agarose gel temperature was around 60ºC, 5μl of Ethidium 
bromide was added. Warm agarose solution was poured slowly into the gel 
platform and kept the gel set undisturbed till the agarose solidifies. 1XTAE buffer 
was poured into submarine gel tank. Place the gel platform carefully into the tank. 
Maintain the tank buffer level 0.5cm above than the gel. 
 
 PCR Samples were loaded after mixing with gel loading dye along with 
10μl HELINI100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 
700bp, 800bp, 900bp,1000bp and 1500bp] 
 
 Run electrophoresis at 50V till the dye reaches three fourth distance of the 
gel. Gel was viewed in UV Transilluminator and the band pattern was observed. 
68 
 
 
Phenotypic confirmatory test for ESBL production- Combined discmethod 
 In this method, a lawn culture was madewiththe test isolates for 
discdiffusion method.  
 
 Ceftazidime (30μg) and ceftazidime-clavulanic acid(30μg/10μg) discs- HI 
media, were placed at a distance of 20mm center to center on the Mueller-Hinton 
agar plate, incubated at 37ºC for 20-24 hours. The testisolate was considered to 
produce ESBL if the zone of inhibition around the ceftazidime-clavulanic acid 
disc was ≥5mm than the zone around ceftazidime disc alone. 
 
  
Results 
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RESULTS 
The present study comprised of 200 randomly selected cases of clinically 
diagnosed Pyoderma, both primary and secondary, attended the Department of 
Dermatology, RGGGH, during the study period March 2017-February 2018. 
Table 1: STUDY GROUP 
Type of Pyoderma Number of cases Percentage 
Primary Pyoderma 58 29% 
Secondary Pyoderma 142 71% 
Total 200 100% 
 
        Among 200 cases of Pyoderma, Primary pyoderma constitute 29% 
Secondary pyoderma constitute 71%, therefore Secondary pyoderma were more 
common than Primary pyoderma in this study. 
 
FIGURE 1 
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Table 2: PATTERN OF PRIMARY PYODERMA 
 
S.No Cinical diagnosis No  of cases Percentage 
1 Folliculitis 16 27.58% 
2 Furunculosis 14 24.14% 
3 Impetigo 12 20.68.% 
4 Cellulitis 5 8.6% 
5 Ecthyma 5 8.6% 
6 Carbuncle 3 5.1% 
7 Paronychia 3 5.1% 
 Total 58 100 % 
 
FIGURE 2 
 
 Among the primary pyoderma, Folliculitis(27.58%) was the most common 
clinical type followed by Furunculosis(24.14%), Impetigo(20.68%), 
Cellulitis(8.6%),ecthyma(8.6%), Carbuncle(5.1%) and Paronychia(5.1%).(table 2)                 
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TABLE-3   PATTERN OF SECONDARY PYODERMA 
 
FIGURE 3 
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S.no Cinical diagnosis No  of cases Percentage 
1 Infected pemphigus 53 37.3% 
2 Bullous pemphigoid 14 9.8% 
3 Ìnfected eczema 15 10.5% 
4 Infected psoriasis 12 8.4% 
5 Infected dermatitis 10 7.0% 
6 Non-healing ulcer 9 6.3% 
7 Infected stasis ulcer 8 5.6% 
8 Infected trophic ulcer 7 4.9% 
9 Infected mycosis 3 2.1% 
10 Pyoderma gangrenosum 5 2.1% 
11 Infected Scabies 2 1.4% 
12 Hidradenitissuppurativa 2 1.4% 
13 Infected keloid 2 1.4% 
 Total 142 100% 
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 Among the  secondary Pyoderma, Infected pemphigus (37.3%) was the  
most common  followed by Eczema with secondary infection(10.5%),bullous 
pemphigoid (9.8%), infected Psoriasis (8.4%),infected dermatitis(7.0%), Non-
healing ulcer(6.3%), infected trophic ulcer(4.9%),infected mycoses 
(2.1%),pyoderma gangrenosum (2.1%),Scabies with secondary infection(1.4%), 
Hidradenitis Suppurativa(1.4%) and infected keloid (1.4%).(table 3) 
 
TABLE-4   SEX DISTRIBUTION 
SEX NO OF  CASES PERCENTAGE 
MALE 117 58.5% 
FEMALE 83 41.5% 
TOTAL 200 100% 
 
FIGURE 4 
 
 
 Out of the 200 cases, 117(58.5%) were males and 83 (41.5%) cases 
wereFemales. The male &female ratio was 1.4:1. (table 4). 
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TABLE-5 DISTRIBUTION OF AGE (IN YEARS) 
AGE IN YEARS 
NO OF 
PATIENTS NO OF 
PATIENTS PERCENTAGE MALE FEMALE 
18-20 6 9 15 7.5% 
21-30 24 20 44 22% 
31-40 18 16 34 17% 
41-50 22 17 39 19.5% 
51-60 23 12 35 17.5% 
61-70 20 7 27 13% 
71 & Above 4 2 6 3% 
TOTAL 117 83 200 100% 
Mean age± SD   43.43 ±16.03  
Significant P-value <0.05 
FIGURE 5 
 
 Pyodermas occurred most commonly in the age group between 21-30years 
(22%) followed by and 41-50 years age group (19.5%) and 51-60(17.5%). Half of 
total cases are in age group between 21-50 years. Pyodermas were less commonly 
occurring in age group 71years and above (4%). 
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TABLE-6A AGE DISTRIBUTION IN RELATION T0 TYPE OF 
PYODERMA 
Age group Primary pyoderma n (%) 
Secondarypyoderma 
n (%) 
Total 
n (%) 
18-20 7(12.3) 8(5.6) 15(7.5) 
21-30 15(26.3) 29(20.3) 44(22) 
31-40 10(17.5) 24(16.8) 34(17) 
41-50 8(14.0) 31(21.7) 39(19.5) 
51-60 8(14.0) 27(18.9%) 35(17.5) 
61-70 7(12.3) 20(14.0) 27(13.5) 
71 & Above 2(3.5) 4(2.8) 6(3) 
Total 57(100) 143(100) 200(100) 
 
FIGURE 6A   AGE DISTRIBUTION IN RELATION T0 PYODERMA 
 
 Primary Pyodermas were more common in the age group 21-30 years 
whereas secondary Pyoderma were more common in the age group 41-50years. 
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Table-6B SEX DISTIBUTION IN RELATION TO PYODERMA 
Sex Primary pyoderma 
Secondary 
pyoderma Total 
Male 27(23.1%) 90(76.9%) 117(100%) 
Female 30(36.1%) 53(63.9%) 83(100%) 
Total 57(100%) 143(100%) 200(100%) 
 
Significant P-Value-  0.05 
FIGURE 6B 
 
 
Table-7 SOCIO-ECONOMIC STATUS 
Socio-economic status No.of patients Percentage(%) 
Low income group 184 92 
Middle income group 15 7.5 
High income group 1 0.5 
Total 200 100 
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FIGURE 7 
 
 High incidence of pyoderma occurred among Low income group (92%) 
followed by middle income group (7.5%). 
 
TABLE-8 OP/IP DISTRIBUTION 
 No. of cases Percentage 
IP 131 65.5% 
OP 69 34.5% 
TOTAL 200 100% 
 
FIGURE 8 
 
Incidence of pyoderma was more in patients admitted in wards than outpatients. 
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TABLE-9        YIELD OF SAMPLES 
Yield of samples No.of cases Percentage 
Culture positive 177 88.5 
Culture negative 23 11.5 
Total 200 100 
 
Figure 9 
 
Among 200 samples, 88.5% were Culture positive and 11.5% were culture 
negative. 
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TABLE-10  GROWTH PATTERN 
 
FIGURE 10 
 
 Single type of organism was grown   in 165 samples (9%) and in 12 
samples (6%) 2 types of organisms were grown and 23 samples showed no 
growth. (table no 10). 
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No growth
Type of isolate Number of cases Percentage 
Single 165 83.5% 
2 types of Organisms 12 5.7% 
No growth 23 16.5% 
Total 200 100 % 
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TABLE-11BACTERIOLOGICAL ANALYSIS 
ISOLATES TOTAL PERCENTAGE 
S.aureus 141 74.6% 
CONS 9 4.8% 
Enterococcus faecalis 1 0.5% 
Beta-hemolytic Streptococci 1 0.5% 
Ps.aeruginosa 11 5.8% 
K.pneumoniae 8 4.2% 
K.oxytoca 2 1.0% 
E.coli 5 2.6% 
P. mirabilis 6 3.2% 
P.vulgaris 1 0.5% 
Acinetobacter baumannii 4 2.1% 
TOTAL 189 100 
 
FIGURE 11 
 
 
 Staphylococcus aureus (74.6%) was the commonest organism isolated 
followed by Pseudomonas aeruginosa (5.8%).  
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TABLE -12 BACTERIAL ISOLATES FROM VARIOUS TYPES OF PYODERMA 
Diagnosis S.
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n (percentage) 
Folliculitis 9 (56.25) 0 0 0 0 0 0 
1 
(6.25) 0 0  0    
1 
(6.25)  
1 
(6.25)  
4 
(25) 
16 
(100) 
Furunculosis 12 (85.7)                   
2 
(14.3) 14 
Impetigo 10 (83.3)                   
2 
(16.7) 12 
Cellulitis 3 (60)                   
2 
(40) 5 
Ecthyma 3 (60)        
1 
(20)   
1 
(20)         5 
Carbuncle 2 (66.7)                  1(33.3)  3 
Paronychia 2 (66.7)                   
1 
(33.3) 3 
Infected 
pemphigus 
34 
(64.2) 
3 
(5.7) 
2 
(3.8) 
1 
(1.9)  
1 
(1.9)    
1 
(1.9) 
1 
(1.9) 
2 
(3.8) 
1 
(1.9)    
1 
(1.9)   
6 
(11.1) 53 
Bullous 
pemphigoid 
11 
(78.6)                   
3 
(21.4 14 
Ìnfected 
eczema 
13 
(86.6)             
1 
(6.7)      
1 
(6.7) 15 
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Infected 
psoriasis 
7 
(58.3) 
3 
(25)             
1 
(8.3)     
1 
(8.3) 12 
Infected 
dermatitis 
9 
(90)         
1 
(10)           10 
Non-healing 
ulcer 
6 
(66.7) 
1 
(11.1)       
2 
(22.2)            9 
Infected 
stasis ulcer 
2 
(25)  
1 
(12.5)  
1 
(12.5)   
1 
(12.5) 
2 
(25)    
1 
(12.5)        8 
Infected 
trophic ulcer 
3 
(42.8)  
2 
(28.6)           
1 
(14.3)      
1 
(14.3) 7 
Infected 
mycosis 
1 
(33.3) 
1 
(33.3)        
1 
(33.3)           3 
Pyoderma 
gangrenosum 
2 
(40)      
1 
(20) 
1 
(20)  
1 
(20)           5 
Infected 
Scabies 
2 
(100)                    2 
Hidradenitis 
suppurativa 
1 
(50)     1(50)               2 
Infected 
keloid 
1 
(50)        1(50)            2 
 
Significant P –Value        0.020 
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TABLE-13   BACTERIOLOGICAL ANALYSIS IN RELATION TO TYPE 
OF PYODERMA 
ISOLATES Primary pyoderma n (%) 
Secondary pyoderma 
n (%) 
S.aureus 41(70.6) 91(64.1) 
CoNS - 9(6.3) 
Enterococcus faecalis - 1(0.7) 
Beta-hemolytic Streptococci - 1(0.7) 
Ps.Aeruginosa 1(1.7) 5(3.5) 
K.pneumoniae - 5(3.5) 
K.oxytoca - 1(0.7) 
E.coli - 2(1.4) 
P.mirabilis 1(1.7) 2(1.4) 
P.vulgaris - 1(0.7) 
Acinetobacter baumannii - 4(2.8) 
S.aureus +Ps.aeruginosa 1(1.7) 2(1.4) 
S. aureus+P.mirabilis - 1(0.7) 
S.aureus+K.pneumoniae 1(1.7) - 
S.aureus+K.oxytoca - 1(0.7) 
S.aureus+E.coli - 2(1.4) 
CoNS+P.mirabilis - 1(0.7) 
Ps.aeruginosa+ K.pneumoniae 1(1.7) - 
Ps.aeruginosa+E.coli 1(1.7) - 
No growth 10(17.2) 13  (9.1) 
TOTAL 58(100%) 142(100%) 
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FIGURE 12 
 
In both primary and secondary pyoderma, S. aureus was the commonest organism 
isolated, followed by Pseudomonas aeruginosa. 
TABLE-14 ANTIBIOTIC SUSCEPTIBITY PATTERN- GPC 
ISOLATES PEN % 
GM 
% 
ERY 
% 
TET 
% 
CIP 
% 
COT 
% 
CK 
% 
LZ 
% 
CX 
% 
HLG 
% 
VAN 
% 
AMP 
% 
S.aureus 12.1 78 43.3 79.4 24.1 56.7 90.8 100 80.1 - - - 
CoNS 22.2 89.6 44.4 66.7 44.4 55.6 100 100 89.6 - - - 
Enterococcus 
faecalis 0 - 0 - 100 - 0 100 - 100 100 0 
Beta 
haemolytic 
streptococci 
0 - 0 100 - 0 - 100 - - 100 100 
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FIGURE 13 
 
 
 S.aureus was most sensitive to Linezolid(100%), chloramphenicol (90.8%) 
and tetracycline (79.4%), followed by Gentamicin (78%) and Cotrimoxazole 
(56.7%). It was least sensitive to Erythromycin (43.3%),ciprofloxacin And 
Penicillin (12.1%)Out of total 141 isolates of S.aureus 113 (80.1%) were sensitive 
to cefoxitin and 28 were resistant. Therefore percentage of MRSA isolated was 
19.9%.  
 
 Among the CONS isolated, 100% were sensitive to chloramphenicol and 
Linezolid each. 89.6% isolates were sensitive to Gentamicin. They were least 
sensitive to Penicillin (22.2%) 2 out of 9 (71.4%) isolates were resistant to 
cefoxitin. Beta hemolytic Streptococci was most sensitive to Ampicillin, 
vancomycin,tetracycline and linezolid, showing 100% sensitivity each and 
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resistant to penicillin, erythromycin and cotrimoxazole. Enterococcus faecalis was 
most sensitive to Vancomycin (100%), linezolid, HLG and Ciprofloxacin and 
resistant to penicillin, Ampicillin, Erythromycin and chloramphenicol 
 
TABLE-15 ANTIBIOTIC SUSCEPTIBITY PATTERN- 
ENTEROBACTERIACEAE 
ISOLATES AK % 
GM 
% 
OF 
% TET 
CTX 
% 
CEC 
% PT AMP 
IMP 
% 
K.pneumoniae 87.5 87.5 87.5 62.5 37.5 100 100 - 100 
K.oxytoca 100 100 50 50 50 100 100 - 100 
Proteus mirabilis 83.3 66.7 83.3 83.3 50 100 100 66.7 100 
Proteus vulgaris 100 0 0 100 100 100 100 0 100 
E.coli 100 60 50 60 40 100 100 60 100 
 
 Klebsiellaspp were most sensitive to Imipenem (100%)and Piperacillin –
tazobactam (100%), followed by Amikacin, Gentamicin and Ofloxacin. They 
were least sensitive to tetracycline and cefotaxime. Proteus spp were most 
sensitive to Imipenem (100%) and least sensitive   to gentamicin (66.7%)and 
cefotaxime. 
 E. coli showed 100% sensitivity to Imipenem, Piperacillin –tazobactam 
and Amikacin. Least sensitive to Gentamicin, Tetracycline, ofloxacin and 
cefotaxime.  
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FIGURE 14 
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TABLE-16 ANTIBIOTIC SUSCEPTIBITY PATTERN-NON-
FERMENTERS 
ISOLATE AK GM CIP COT PT CAZ IMP TET 
Ps.aeruginosa 
 81.8% 72.7% 54.5% 37.5% 100% 60% 100% 72.7% 
Acinetobacter 
baumannii 75% 75% 50% 75% 75% 75% 75% 
50% 
 
 
 Ps. aeruginosa were most sensitive to Imipenem, Piperacillin-tazobactam 
followed by Amikacin, Gentamicin, Tetracyclines and least sensitive to 
Ciprofloxacin and Cotrimoxazole. 
 
TABLE-17 ANTIBIOTIC SUSCEPTIBILITY PATTERN BETWEEN 
MSSA AND MRSA 
Antibiotic 
MSSA (n-113) MRSA(n-28) 
Sensitive 
n   % 
Resistant 
% 
Sensitive 
% 
Resistant 
% 
PEN 14.3 85.7 3.6 96.4 
GM 82.3 17.7 60.7 39.3 
ERY 50.4 49.6 14.3 85.7 
TET 85.0 15.0 57.1 42.9 
CIP 27.4 72.6 10.7 89.3 
COT 59.3 40.7 46.7 53.6 
MUP 100% 0 89.3% 10.7% 
CK 96.5 3.5 67.9 32.1 
LZ 100 0 100 0 
Significant P-value <0.05  
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 Both MSSA and MRSA were most sensitive to linezolid, and least 
sensitive to penicillin. MSSA were more sensitive to chloramphenicol, 
tetracycline, gentamicin and erythromycin than MRSA. 
 
FIGURE 15 
 
 
MRSA VS MSSA 
FIGURE 16 
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TABLE-18 MUPIROCIN SUSCEPTIBILITY AMONG MRSA ISOLATES 
MRSA 
Isolates 
Mupirocin 
Disc Diffusion 
MUP(200mcg) E-Test PCR For mup A 
28 
Sensitive Resistant ≤1 2-256 ≥256 Positive Negative 
25(89.3%) 3(10.7%) 25 - 3 3(10.7%) 25(89.3%) 
 
   Among 28 MRSA isolates, 25 were mupirocin sensitive and 3 were resistant. 
 
FIGURE 17 
 
 
ESBL PRODUCERS AMONG ENTEROBACTERIACEAE ISOLATES 
FIGURE 18 
 
Among 21 Enterobacteriaceae isolates, 10(47.6%) were ESBL producers.  
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DISCUSSION 
 
 Bacterial skin infections become one of the most common clinical problem 
encountered in many fields of clinical medicine10.Pyoderma is the generic term 
used to describe any variant of superficial bacterial skin infection. 8 Pyoderma 
constitutes a major portion amongpatients attending dermatological clinics in 
India. 
 
 The present study comprised of 200 randomly selected cases of both 
primary and secondary Pyoderma, attended the Department of Dermatology, 
RGGGH, during the study period March2017 to February 2018, to identify the 
causative organism of both primary and secondary Pyodermas and also to 
determine their latest antibiotic susceptibility pattern. 
 
 In the present study, out of the 200 cases of Pyoderma, Secondary 
pyodermas constituted 71% of the cases and the remaining 29% constituted 
Primary pyoderma(Table-1). Thus, showing that secondary pyodermas were more 
common than primary pyoderma which is similar to the study conducted by 
Harshita et al which showed 68.13% secondary pyodermas and 31.87% of cases 
were primary pyodermas 96. Malhotra SK et al which showed 80.33% cases of 
secondary pyodermas and 19.67% cases were primary pyoderma10. Sravani BVN, 
Kumar BS, Mavuri VVNR, et al. showed that secondary pyoderma accounted for 
76% cases while 24%  of cases were primary pyoderma.94 
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 Few studies showed that primary pyodermas were more common than 
secondary pyoderma. In our study low incidence of primary pyoderma may be 
due to the fact that patients less than 18 years were excluded from this study and 
inpatients (65.5%) were more than outpatients (34.5%). 
 
 Incidence of pyoderma (table-4) was more in Males (58.5%) than females 
(41.5%) which correlates well with other studies.94,95,96 
 
 Present study showed that most of the patients belonged to the lower 
socioeconomic group (92%) followed by middle socioeconomic group(7.5%).only 
0.5% of higher socioeconomic group presented with Pyoderma(table-8). This 
correlates well with many other studies.24 
 
 In this study, most of the cases of pyoderma i.e. 78(39%) belongs to the 
age group 21-40 years (Table-5). Mean age was found to be 43.43±16.03. This is 
similar to the study reported by Ghadage D P, Sali Y A. et al, which showed 
42(36.5%) cases in the age group of20-40 years.9 
 
 Primary pyodermas occurred most frequently in the age group of 21-30 
years( 26.3%)(table-6), which is similar to the study conducted by Ashokan C et 
al, which showed Primary pyodermas were seen most frequently in the age group 
of 21-30 years with 28%( 63/225 cases).97 
 
 Secondary pyodermas were common in the age group of 41-50 years 
(21.7%) followed by 21-30 years (20.3%) (table-6)in the present study. 
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 In the present study, among the primary pyoderma, Folliculitis (27.58%) 
was the most common clinical type followed by Furunculosis (24.14%), Impetigo 
(20.68),Cellulitis (8.6%),ecthyma (8.6%), Carbuncle (5.1%)and Paronychia 
(5.1%). (table-2). This is similar to the study conducted by Paudel U et al showed 
that Folliculitis (26.7%) was the commonest followed by Furunculosis (22.7%)95. 
Although many studies have shown impetigo as the commonest lesion, however 
majority of our patients were adults which accounts for high frequency of 
folliculitis in this study. 
 
 In our study, among the secondary pyodermas, Infected 
pemphigus(vulgaris + foliaceus+ erythematosus) (37.3%) was the  most common  
followed by Eczema with secondary infection(10.5%), infected bullous 
pemphigoid (9.8%), infected Psoriasis (8.4%),infected dermatitis(7.0%), Non-
healing ulcer(6.3%),  infected trophic ulcer(4.9%),infected mycoses 
(2.1%),pyoderma gangrenosum (2.1%),Scabies with secondary infection(1.4%), 
Hidradenitis Suppurativa(1.4%) and infected keloid (1.4%).(table-3). 
 
 Infected pemphigus (37.3%) was the   commonest type which is similar to 
studies conducted by Sravani BVN, et al where Infected pemphigus constituted 
44% of total cases94 and also by Malhotra, et al. where Infected pemphigus 
constituted 39.34%10. 
 
 Among 200 samples processed in our study,177 samples(88.5%) were 
culture positive( growth +)whereas 23( 11.5%)samples were culture negative (no 
growth) (table-9).Among culture positive, single type of organism was grown in 
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165 samples(94%),more than 1 type of  organism were grown in 12 
samples(6%)(table-10).This correlates well  with the study conducted  by Rani SR 
et al which showed  that among 135 cases which yielded growth, 97 cases showed 
monomicrobial infection while 38 cases showed mixed infection98. 
 
 In bacteriological analysis of our study, a total of 189 isolates were 
obtained.Among which 50 isolates were obtained from 58 primary pyoderma 
cases and 139 isolates were obtained from  142 secondary pyoderma cases .We 
observed that Staphylococcus aureus (74.6%), was the most common organism 
isolated followed  by Pseudomonas aeruginosa (5.8%), Klebsiellaspecies(5.2%) ,  
Coagulase negative Staphylococci(4.8%)  , Proteus species(3.7%) , Escherichia 
coli (2.6%) , Acinetobacter baumannii (2.1%) Enterococcus faecalis and beta 
hemolytic Streptococci   (0.5%) (table no.10 ) 
 
 In the present study among 200 cases, the most common pathogen isolated 
was S.aureus (74.6%). Similar findings have been reported by other workers. 
However, there was no significant difference between the isolation of S. aureus in 
primary and secondary pyoderma, the percentage being 75.4% and 68.5% 
respectively with a P value of 0.434, which correlates with the study of Paudel et 
al.95Enterococcus faecalis (0.5%) was isolated only in 1 patient in this study 
which is similar to the study of Paudel et al.95 
 
 There was low incidence of Streptococci which was isolated only in 1 
patient (0.5%), which is similar to the study done by PihuSethi&JayadevBetkerur 
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et al101. But 2.3% to 9% of Beta- hemolytic Streptococci have been isolated by 
many others. 
 
 4.8% of Cons was isolated in the present study. However ,the  percentage 
of isolation has been variable in other studies for example 23.61% were CoNS by 
Ghadage D P, Sali Y A. et al.9 
 
 Among the Gram-negative bacilli, Pseudomonas aeruginosa (5.8%) was 
the most common isolate in the present study, which is similar to the study 
conducted by Janardhan. B et al, they isolated (7%) Pseudomonas species99. 
 
               Present study showed that S.aureus was the most common organism 
isolated  which was 100% sensitive to linezolid and Chloramphenicol(90.8%) and 
tetracycline (79.4%), followed by Gentamicin (78%) and Cotrimoxazole (56.7%). 
It was least sensitive to Erythromycin (43.3%), ciprofloxacin (24.1) And 
Penicillin (12.1%)(table-14). This is similar to the study conducted by Prateek 
Kamble et al showed thatPenicillin was least sensitive (14.26%) probably due to 
the penicillinase producing strains. Similar findings have been shown by other 
workers also.11 
 
 Among the CONS isolated, 100% were sensitive to chloramphenicol and 
Linezolid each. 89.6% isolates were sensitive to Gentamicin. They were least 
sensitive to Penicillin (22.2%). This is similar to other studies conducted by  
Prateek Kamble et al showed sensitivity of  aminoglycoside(80-90%)11 and  
Malhotra et al (2012) also suggested high (77.7%) aminoglycoside sensitivity10. 
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 Beta hemolytic Streptococci was most sensitive to Ampicillin, 
Vancomycin, Tetracycline and Linezolid, showing 100% sensitivity each and 
resistant to Penicillin, Erythromycin and Cotrimoxazole.  
 
 Enterococcus faecalis was most sensitive to Vancomycin (100%), 
Linezolid, HLG and Ciprofloxacin and resistant to Penicillin, Ampicillin, 
Erythromycin and Chloramphenicol. This correlates with the study conducted by 
Harshita et al. showed that i.e. 100% sensitive to Linezolid and maximum 80%   
resistance to Ampicillin96. 
 
 Among gram negative bacilli, Pseudomonas aeruginosa were most 
sensitive to Imipenem and Piperacillin-tazobactam (100%) followed by Amikacin 
(81.8), Gentamycin and Tetracyclines (72.7%)each and least sensitive to 
Ceftazidime (60%), Ciprofloxacin (54.5%) and Cotrimoxazole(37.5%)(table-
16).This was similar to the study conducted by Ghadage D P, Sali Y A et al 
showed that Pseudomonas species were more sensitive to Amikacin (72%) and 
Carbenicillin (57%) and least sensitive to Cotrimoxazole (10%)9. 
 
 In the present study, Klebsiellaspp were 100% sensitive to Imipenem and 
Piperacillin–tazobactam, followed by Amikacin, Gentamicin and Ofloxacin 
(87.5%)each. They were least sensitive to Tetracycline (62.5%) and 
Cefotaxime(37.5%)(table-15), which was similar to the study conducted by 
Malhotra SK et al, showed 50% resistant to Cefotaxime10. 
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 Proteus spp were more sensitive to Imipenem (100%) and least sensitive 
togentamycin (66. 7%). E. coli showed 100% sensitivity to Imipenem, 
Piperacillin–tazobactam and Amikacin. Least sensitive toGentamicin (60%), 
Tetracycline (60%),Ofloxacin (50%) and cefotaxime (40%) Acinetobacter 
baumannii were more sensitive to imipenem, piperacillin-tazobactam, 
ceftazidime, cotrimoxazole 75% each and least sensitive to ciprofloxacin and 
tetracycline. Amikacin, Gentamycin All the Gram-negative isolates showed 
100%sensitivity to Imipenem and most of the strains were resistant to one or more 
antibiotics. 
 
 Out of total 141 isolates of S. aureus 113 (81%) were sensitive to cefoxitin 
and 28were resistant. Therefore, the percentage of MRSA isolated was 
19.9%(table-14).  2 (22.2%)out of 9 isolates of CoNS were resistant to 
cefoxitin,22.2% of Marcon’s were isolated. 
 
 Antibiotic resistance pattern among MRSA and methicillin sensitive S. 
aureus (MSSA) isolates were compared which showed that resistance to 
ciprofloxacin (89.3%), erythromycin (85.7%) and penicillin (96.4%) were 
significantly higher in MRSA isolates than MSSA isolates (p<0.05) (Table -17).  
 
 The present study shows a relatively high rate of susceptibility pattern 
among the clinically isolated MSSA to tetracycline (85%), Gentamycin 
(82.3%)and chloramphenicol (96.5%). Similar findings were observed in the 
study conducted by Prateek Kemble et al showed that resistance to 
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fluoroquinolones as well as to other antibiotics tested was significantly higher in 
MRSA than MSSA isolates11. 
 
 In the present study among 28 MRSA isolates,3 (10.7%) isolates were 
found to be High level mupirocin resistant by disc diffusion test, E-test, and by 
PCR for mup A gene(table-18) and no discrepancies was observed between the 
disc diffusion and   E-test MIC values and mup A PCR.MSSA isolates were 100% 
sensitive to mupirocin by disc diffusion method. Few studies had reported 
mupirocin resistance. 
 
 In a study conducted by Ravisekhar Gadepalli, and Benu Dhawan, they 
first reported the extent of mupirocin resistance in an Indian hospital, it was found 
that High-level mupirocin resistance was detected in 10(5%) of the 200 S. aureus 
isolates, among which 9 of 110 (8.2%) were MRSA isolates and 1 of 90 (1.1%) 
MSSA isolates103. Hodiwala Anahita et al. reported that 16.6% was high level 
resistant to mupirocin100. 
 
 B. Madhumati et al states that out of 108 MRSA strains, 26 (24%) were 
mupirocin resistant Staphylococcus aureus. High-level mupirocin resistance was 
reported in 11%21. 
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SUMMARY 
 
 The present study was carried out on 200 randomly selected cases of 
pyoderma, both primary and secondary, attending dermatology outpatient 
and inpatient department in RGGGH, for bacteriological profile and 
antibiotic susceptibility pattern.  
 Secondary pyoderma was more common than Primary pyoderma. Infected 
pemphigus was   the commonest clinical type followed byfolliculitis. 
 The incidence of pyoderma was found to be high in males than females, 
with the male to female ratio being 1.4:1. 
 Most of the patients belonged to the adult age group. Maximum number of 
cases are in the age group 21-40 years (39%). 
 Majority of the patients belongs to the lower income group. 
 Among 200 samples processed 177 yielded growth whereas 23 samples 
showed no growth. Out of 177 cases that yielded growth 165 cases showed 
only one type of organism whereas 12 cases showed two types of 
organisms. 
 Staphylococcus aureus (74.6%), was the most common organism isolated 
from both primary and secondary pyoderma followed by Pseudomonas 
aeruginosa (5.8%). 
 S. aureus was the most common organism isolated which was 100% 
sensitive to linezolid followed by Chloramphenicol (90.8%), tetracycline 
(79.4%), Gentamicin (78%) Cotrimoxazole (56.7%)and Erythromycin 
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(43.3%). Most of the isolates were resistant to ciprofloxacin (75.9%) and 
penicillin (87.9%). 
 Out of total 141isolates of S. aureus ,113(80.1%) were MSSA and 
28(19.9%) wereMRSA. Among 28 MRSA isolates ,25(89.3%)were 
Mupirocin  sensitive and 3 (10.7%) were high-level mupirocin resistant 
 All the Gram negative isolates showed 100%sensitivity to Imipenem and 
most of the strains resistant to one or more antibiotics. 
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CONCLUSION 
 
 Bacterial skin infection is one of the commonest clinical problem 
encountered in day to day clinical practice. Among which Pyoderma or pyogenic 
infection of skin constitute major portion.  Their management is complicated by 
the emergence of multidrug resistance among the commonly isolated etiological 
agents, thus limiting the treatment options. If not treated promptly they lead to 
recurrence of the disease and various other complications.  With the advent of 
wide range of topical preparations containing broad spectrum antibiotics and 
chemotherapeutic agents, emergence of multidrug resistant organism become a 
great concern. Use of a particular antibiotic at therapeutic or sub- therapeutic 
levels were known to induce resistance by microorganism.  
 
 With the knowledge of common causative organism and their resistance 
pattern, proper antibiotic therapy can be given, thus avoiding unnecessary 
medication and also keep newer antibiotics in reserve for use only when necessity 
arises. Therefore, timely recognition, and prompt bacterial diagnosis and 
antibiotic susceptibility testing is very important for the management of pyoderma 
and also to prevent further major complications. 
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PROFORMA 
 
 Name :                                                                      IP  NO: 
 Age:                                                                          Ward: 
 Sex: 
 Occupation: 
 Address: 
 
 
 
 Presenting complaints 
 
 
 
 Personal history 
 
 
 Past history 
 
 Prior antibiotic  therapy 
 
 Clinical Diagnosis: 
 
 
 Microbiological  investigation: 
 Direct Gram staining : 
 
 Culture :          Blood Agar- 
ChocolateAgar -  
Mac Conkey Agar- 
 Organism identified/Speciation: 
 
          Antimicrobial susceptibility pattern – 
             
           PCR for mupA gene - 
  
 
CONSENT FORM 
 
 
STUDY TITLE :  
A STUDY ON BACTERIOLOGICAL PROFILE OF PYODERMA   IN A 
TERTIARY CARE HOSPITAL 
 
 I…………………………………………, hereby give consent to participate in 
the study conducted by Dr.S.KOKILA, Post graduate at Institute of Microbiology, 
Madras Medical College, Chennai and to use my personal clinical data and the result of 
investigations for the purpose of analysis and to study the nature of the disease, I also 
give consent to give my clinical Specimen  for further investigations. I also learn that 
there is no additional risk in this study. I also give my consent for my investigator to 
publish the data in any forum or journal. 
 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
Patient Name & Address: 
 
Signature of the Investigator: 
 
  Signature of the Guide: 
     
  
 INFORMATION SHEET 
 
STUDY TITLE : A STUDY ON BACTERIOLOGICAL PROFILE OF 
PYODERMA    
                                    IN A TERTIARY CARE HOSPITAL  
 
 
INVESTIGATOR  : Dr.S.Kokila, 
                                    I yr Post Graduate, 
    Institute of Microbiology, 
  Madras Medical College, 
  Chennai - 600003 
 
GUIDE   : Dr. R.Vanaja M.D., 
                                     Professor of Microbiology, 
                                     Institute  of  Microbiology, 
                                     Madras  Medical  College, 
                                     Chennai - 600003 
 
 In recent times, the emergence of antibiotic resistance has significantly poses a 
serious threat to public health .For the successful treatment of pyodermas, various 
causative organisms and their sensitivity patterns in local area is essential. The present 
study aimed to find out the causative organisms and their antibiotic susceptibility 
patterns in pyodermas in the Dermatology department  in a tertiary care hospital. 
 
I am going to detect the prevalence of Mupirocin  resistance among the   MRSA  
isolates and their  susceptibility in this tertiary hospital. I am going to collect two sterile 
swabs for this study and process them accordingly.200 patients are included in this study 
after getting informed consent only. This study is entirely voluntary and patient can 
withdraw any time from this study. Extra cost will not be incurred to the patients in this 
study. Any doubt regarding this study will be willingly clarified. Results of the study will 
be published. In case of any doubt please contact Dr.S.Kokila,  Cell: 9626759625. 
  
 
  
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
1 59896 44 34 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus S S S S S S S S S MSSA S
2 58969 44 44 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S R R R R S S R MRSA S S NEGATIVE
3 59923 45 29 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R S R S S S S MSSA S
4 55144 44 60 M LOW CARBUNCLE PRI 1 S.aureus R S S S R S S S S MSSA S
5 31477 45 57 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R S R S S S S MSSA S
6 29291 OP 52 M LOW DERMATITIS SEC 1 S.aureus R S R S S S S S S MSSA S
7 72373 45 56 F LOW
PEMPHIGUS 
VULGARIS
SEC 2 S.aureus R S R S S R S S S MSSA S
Proteus mirabilis S S S S S S S S S
8 75303 44 75 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 CoNS R S R R R R S S R MRCoNS
9 65088 44 47 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R S R S S S R MRSA R R  POSITIVE
10 129634 OP 35 M LOW ECZEMA SEC 1
Klebsiella 
pneumoniae
S S S S S S S S
11 81913 45 37 F LOW
PEMPHIGUS 
VULGARIS
SEC 1
Enterococcus  
faecalis
R R R R S S R
12 82582 44 46 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R S R S S S S MSSA S
13 76222 45 35 F LOW
PEMPHIGUS 
VULGARIS
SEC 2 CoNS R S R R R R S S R MRCoNS
Proteus mirabilis R S R R S S R S S ESBL
14 709778 OP 29 F LOW FOLLICULITIS PRI 2 S.aureus R S R S R S S S R MRSA S S NEGATIVE
Klebsiella 
pneumoniae
S R S S S R S S ESBL
15 55517 OP 60 M LOW STASIS ULCER SEC 2 S.aureus R R R R R R R S R MRSA S S NEGATIVE
Proteus mirabilis S S S S S S S S S
16 167370 OP 42 F LOW FOLLICULITIS PRI NG
17 120436 44 45 M LOW
PSORIASIS 
VULGARIS
SEC 1 CoNS S S R S S S S S S MSCoNS
18 121896 44 55 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R R S S S MSSA S
19 671123 OP 51 M HIGH FURUNCULOSIS PRI 1 S.aureus R S R S R S S S R MRSA S S NEGATIVE
20 12751 45 55 F LOW
PSORIASIS 
VULGARIS
SEC NG
21 105517 OP 40 M LOW ECZEMA SEC 2 S.aureus R S S S S S S S S MSSA S
E.coli S R S S S R S S ESBL
MASTER CHART
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
22 126574 44 75 M LOW TROPHIC ULCER SEC 1
Klebsiella 
pneumoniae
S S S S S S S S
23 125036 44 55 M MIDDLE
PEMPHIGUS 
VULGARIS
SEC 1
Klebsiella 
pneumoniae
S R S S R R S S ESBL
24 171116 OP 51 M LOW STASIS ULCER SEC 1 Klebsiella  oxytoca S S S S S S S S
25 47219 45 20 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R S S S MSSA S
26 14860 45 48 F MIDDLE FOLLICULITIS PRI NG
27 131426 45 60 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R R S S S MSSA S
28 556480 OP 18 F LOW IMPETIGO PRI 1 S.aureus R R R R R S S S S MSSA S
29 936490 OP 18 M LOW
INFECTED 
MYCOSES
SEC 1 CoNS S S S S S S S S S MSCoNS
30 135690 44 36 M LOW DERMATITIS SEC 1 S.aureus S S S S S R S S S MSSA S
31 135750 44 65 M LOW
INFECTED 
MYCOSES
SEC 1 S.aureus R S S S R R S S S MSSA S
32 136838 45 55 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus S S S S R S S S S MSSA S
33 128531 44 28 M MIDDLE
HIDRADENITIS 
SUPPURATIVA
SEC 1 E.coli R S S S S R S S ESBL
34 137148 45 29 F LOW
PYODERMA 
GANGRENOSUM
SEC 1 Proteus  vulgaris R R R R S S S S
35 504360 OP 47 M LOW STASIS ULCER SEC 1 Proteus mirabilis S S S S S S S S S
36 520000 OP 18 M LOW
PUSTULAR 
PSORIASIS
SEC 2 S.aureus R R R S R S S S S MSSA S
Klebsiella  oxytoca S R S R S R S S
37 131675 44 60 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R R R R R R S S S MSSA S
38 29291 OP 52 M LOW DERMATITIS SEC 1 S.aureus R S R R R R S S S MSSA S
39 25930 26 29 M LOW
INFECTED 
WOUND
SEC 1 CoNS R S S S S S S S S MSCoNS
40 118998 45 82 F LOW
PEMPHIGUS 
FOLIAECEOUS
SEC NG
41 111600 44 42 M LOW
NON-HEALING 
ULCER
SEC 1
Pseudomonas 
aeruginosa 
R R S R S S R S
42 109430 44 47 M LOW
INFECTED 
WOUND
SEC 1 S.aureus R R R S R S S S S MSSA S
43 34280 44 60 M LOW
PEMPHIGUS 
FOLIAECEOUS
SEC 1 S.aureus R S R R R R S S S MSSA S
44 131960 45 23 F LOW IMPETIGO PRI 1 S.aureus R S R R R R S S R MRSA S S NEGATIVE
45 59508 OP 27 M LOW DERMATITIS SEC 1 S.aureus R S R S R R S S S MSSA S
46 365033 OP 48 F LOW VARICOSE ULCER SEC 1
Klebsiella 
pneumoniae
S S S S S R S S ESBL
47 144024 OP 52 M MIDDLE FURUNCULOSIS PRI 1 S.aureus S S S S R S S S S MSSA S
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
48 48848 OP 53 F LOW TEN PRI NG
49 132674 44 61 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S S S R S S S S MSSA S
50 132718 45 30 F LOW FOLLICULITIS PRI 2
Klebsiella 
pneumoniae
R S S R S R S S ESBL
Pseudomonas 
aeruginosa 
S S S R S S S S
51 10646 44 34 M LOW FURUNCULOSIS PRI 1 S.aureus R S S S R S S S S MSSA S
52 114528 OP 20 M MIDDLE
ATOPIC 
DERMATITIS
SEC 1 S.aureus R S R S R S S S S MSSA S
53 11332 13 35 F LOW TROPHIC ULCER SEC 2 S.aureus R S R S R S S S S MSSA S
E.coli S S S S S S S S
54 18696 44 45 M LOW
PEMPHIGUS 
VULGARIS
SEC 1
Acinetobacter 
baumanii
R R R R R R R R
55 105231 OP 40 M LOW FURUNCULOSIS PRI NG
56 171500 OP 48 M LOW STASIS ULCER SEC 1 S.aureus R S R S R R S S S MSSA S
57 17245 44 67 M LOW TEN PRI 1 S.aureus R S R S R R S S R MRSA S S NEGATIVE
58 68734 45 25 F MIDDLE
INFECTED 
KELOID 
SEC 1
Pseudomonas 
aeruginosa 
S S S S S S S S
59 172367 OP 66 F LOW CELLULITIS PRI 1 S.aureus R S S S R S S S S MSSA S
60 593450 44 25 M LOW IMPETIGO PRI 1 S.aureus R S S S R S S S S MSSA S
61 62058 44 60 M LOW
PEMPHIGUS 
FOLIAECEOUS
SEC 1 S.aureus R R R S R S S S R MRSA S S NEGATIVE
62 105175 44 35 M LOW
PSORIATIC 
ERYTHRODERMA
SEC 1 S.aureus R S R S R R S S S MSSA S
63 14239 44 39 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R S R R S S S MSSA S
64 106174 OP 18 M LOW IMPETIGO PRI 1 S.aureus R R R S S R S S R MRSA R R POSITIVE
65 14894 45 30 F LOW VARICOSE ULCER SEC 1
Pseudomonas 
aeruginosa 
S S S S S S S S
66 15298 45 30 F LOW ECTHYMA PRI 1 S.aureus R S R R R S S R S MSSA S
67 14786 44 35 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus S S S S R S S S S MSSA S
68 714123 45 52 F LOW
PEMPHIGUS 
VULGARIS
SEC NG
69 14789 44 31 M LOW FURUNCULOSIS PRI 1 S.aureus R S S S R S S S S MSSA S
70 15357 45 27 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R S S S S MSSA S
71 15710 44 45 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R R R S R S R MRSA R S NEGATIVE
72 17239 44 70 M LOW DERMATITIS SEC 1 S.aureus S S R S S S S S R MSSA S
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
73 180166 OP 30 F LOW FURUNCULOSIS PRI 1 S.aureus R R S S S R R S R MRSA S S NEGATIVE
74 11168 45 25 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R R R R S S R MRSA S S NEGATIVE
75 11237 OP 30 M LOW IMPETIGO PRI 1 S.aureus R S S S S R S S S MSSA S
76 19538 30 18 M LOW CELLULITIS PRI 1 S.aureus R R S R R S S S R MRSA S S NEGATIVE
77 15941 OP 50 F LOW ECTHYMA PRI 1 S.aureus R R R R R R R S R MRSA S S NEGATIVE
78 19375 30 50 M LOW
INFECTED 
WOUND
SEC 1 S.aureus R S S S R S S S S MSSA S
79 18325 OP 30 M LOW IMPETIGO PRI 1 S.aureus R S S S R R S S S MSSA S
80 20703 44 70 M LOW
PSORIASIS 
VULGARIS
SEC 1 CoNS R R R S R R S S S MSCoNS
81 12550 45 25 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R S S R S S S MSSA S
82 12486 45 30 F LOW FOLLICULITIS PRI NG
83 962986 OP 29 M LOW DERMATITIS SEC 1 S.aureus R R R R R R R S S MSSA S
84 45763 30 22 M LOW
INFECTED 
WOUND
SEC 1 S.aureus R S S S R S S S S MSSA S
85 15358 45 27 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R S R R S S S MSSA S
86 17310 13 49 M LOW TROPHIC ULCER SEC NG
87 116566 OP 28 M MIDDLE FOLLICULITIS PRI 1 S.aureus R S R S R S S S S MSSA S
88 106923 45 37 F LOW FOLLICULITIS PRI 1 S.aureus S S R S R R S S S MSSA S
89 23694 44 34 M LOW FURUNCULOSIS PRI 1 S.aureus S S R S R S S S S MSSA S
90 12430 OP 21 F LOW
INFECTED 
SCABIES
SEC 1 S.aureus R S R S R S S S S MSSA S
91 23649 44 65 M MIDDLE FOLLICULITIS PRI 1 S.aureus S S R R R S S S S MSSA S
92 31513 13 42 F LOW TROPHIC ULCER SEC 1 S.aureus R S R S R S S S S MSSA S
93 26009 45 25 F LOW FURUNCULOSIS PRI 1 S.aureus R S R S R R S S S MSSA S
94 25095 45 25 F MIDDLE
UNSTABLE 
PSORIASIS
SEC 1 S.aureus R R R S R S S S R MRSA S S NEGATIVE
95 29012 45 30 F LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S S S R R S S S MSSA S
96 30640 44 68 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S S S S S S S S MSSA S
97 30613 45 50 F LOW
PYODERMA 
GANGRENOSUM
SEC 1
Acinetobacter 
baumanii
S S R S S S S S
98 117947 45 35 F LOW
PEMPHIGUS 
VULGARIS
SEC NG
99 30343 45 65 F LOW
PYODERMA 
GANGRENOSUM
SEC 1 Proteus mirabilis R R S S R S S ESBL
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
100 132711 OP 50 M LOW
NON-HEALING 
ULCER
SEC 1 S.aureus R S R S R R S S R MRSA S S NEGATIVE
101 63005 44 60 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 E.coli R S S S S S S S
102 610258 OP 25 F LOW IMPETIGO PRI 1 S.aureus R S S S S S S S S MSSA S
103 610044 OP 24 M LOW ECZEMA SEC 1 S.aureus R S S S R S S S S MSSA S
104 37490 44 58 M LOW
PSORIATIC 
ERYTHRODERMA
SEC 1 S.aureus R S S S R S S S S MSSA S
105 32473 44 60 M LOW ECTHYMA PRI 1
Pseudomonas 
aeruginosa 
S S S S S S S S
106 90043 44 65 M LOW TEN PRI 1 S.aureus R S R R R S S S R MRSA S S NEGATIVE
107 94070 45 45 F LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S R S R S S S S MSSA S
108 78628 45 68 F LOW
PEMPHIGUS 
ERYTHEMATOSU
SEC 1 S.aureus R S S S S R S S S MSSA S
109 383955 OP 61 M LOW  ECZEMA SEC 1 S.aureus R S R S R S S S S MSSA S
110 39477 44 54 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S R S R S S S S MSSA S
111 70385 45 60 F LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R R R S R R R S R MRSA S S NEGATIVE
112 92108 44 54 M LOW
PSORIASIS 
VULGARIS
SEC 1 S.aureus R S R S S S S S S MSSA S
113 98663 45 62 F MIDDLE CARBUNCLE PRI 1 S.aureus R S S S R S S S S MSSA S
114 137148 45 2 F LOW
PYODERMA 
GANGRENOSUM
SEC 1 S.aureus S S S S S S S S S MSSA S
115 125485 45 70 F LOW
BULLOUS 
PEMPHIGOID
SEC NG
116 78364 44 69 M LOW ECZEMA SEC 1 S.aureus R R S S R S S S S MSSA S
117 647110 OP 28 M LOW
HIDRADENITIS 
SUPPURATIVA
SEC 1 S.aureus R S S S S S S S S MSSA S
118 67591 45 27 F LOW
PEMPHIGUS 
FOLIAECEOUS
SEC 1 S.aureus R S S S R S S S S MSSA S
119 16023 OP 50 F LOW FOLLICULITIS PRI 1 S.aureus S S S S S S S S S MSSA S
120 103576 OP 42 M MIDDLE FOLLICULITIS PRI 1 S.aureus R R R S R R S S R MRSA S S NEGATIVE
121 111952 OP 25 M LOW
INFECTED 
SCABIES
SEC 1 S.aureus R S R S R R R S S MSSA S
122 169540 OP 66 M LOW  ECZEMA SEC 1 S.aureus R S R S R S S S S MSSA S
123 25061 44 25 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R S S S R MRSA S S NEGATIVE
124 93959 44 54 M LOW
PEMPHIGUS 
VULGARIS
SEC NG
125 58244 45 30 F LOW
PUSTULAR 
PSORIASIS
SEC 1 S.aureus R S R S S S S S S MSSA S
126 30826 44 76 M LOW ECZEMA SEC 1 S.aureus R S R S R S S S R MRSA S S NEGATIVE
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
127 120356 45 45 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R R S S S MSSA S
128 120436 45 44 M LOW
PSORIASIS 
VULGARIS
SEC 1 S.aureus R R R R R R R S S MSSA S
129 356180 OP 54 M LOW FOLLICULITIS PRI 1 S.aureus R S R S R R S S S MSSA S
130 127120 OP 48 M LOW ECZEMA SEC 1 S.aureus R S R S R S S S S MSSA S
131 8970 OP 37 F LOW IMPETIGO PRI 1 S.aureus R S S S S R S S S MSSA S
132 124354 OP 54 M LOW DERMATITIS SEC 1 S.aureus S S S S S R S S S MSSA S
133 37570 44 19 M LOW
ATOPIC 
DERMATITIS
SEC 1 S.aureus R S S S R R S S S MSSA S
134 37557 45 30 M LOW
PEMPHIGUS 
VULGARIS
SEC 1
Betahemolytic 
Streptococci
R - R - S R S S S
135 39132 45 45 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 CoNS R S S S S S S S S MSCoNS
136 87161 45 52 F LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus S S R S S S S S S MSSA S
137 30613 45 50 F LOW
PYODERMA 
GANGRENOSUM
SEC 1 S.aureus R R R R R R R S R MRSA S S NEGATIVE
138 29012 45 31 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R R R R S S S MSSA S
139 38065 45 26 F LOW
PEMPHIGUS 
VULGARIS
SEC 2 S.aureus R S R R R R R S R MRSA S S NEGATIVE
Pseudomonas 
aeruginosa 
S R R R S S R S
140 39611 45 35 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R S R S S S S MSSA S
141 507344 OP 18 M LOW FURUNCULOSIS SEC NG
142 40050 45 50 F LOW
PEMPHIGUS 
VULGARIS
SEC 2 S.aureus R R R S R R S S S MSSA S
Pseudomonas 
aeruginosa 
S S S R S S S S
143 45206 44 32 M LOW
INFECTED 
WOUND
SEC 1 S.aureus R S R R R S S S S MSSA S
144 223874 OP 40 M LOW  ECZEMA SEC 1 S.aureus R S R S R R S S R MRSA S S NEGATIVE
145 1402 45 24 F LOW FURUNCULOSIS PRI 1 S.aureus R S R R R S R S R MRSA S S NEGATIVE
146 1203671 OP 50 M LOW CELLULITIS PRI 1 S.aureus R S S S R S S S S MSSA S
147 53208 OP 68 M LOW  ECZEMA SEC 1 S.aureus R S S S S S S S R MRSA S S NEGATIVE
148 575233 45 25 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 CoNS R S R R R R S S S MSCoNS
149 40773 45 60 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R R R R S S S MSSA S
150 103735 44 35 M LOW DERMATITIS SEC 1
Acinetobacter 
baumanii
S S S S S S S
151 17314 45 20 F LOW FOLLICULITIS PRI 1 Proteus mirabilis S S S S S S S S
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
AGE SEX
SE 
status
Diagnosis
primary 
/secondary 
pyoderma
SINGLE/  TWO 
TYPE OF 
ORGANISM
organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
152 37557 44 30 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R R R R S S S MSSA S
153 5136 OP 45 F LOW
INFECTED 
MYCOSES
SEC 1
Acinetobacter 
baumanii
S R S S S S S S
154 11162 45 31 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R R R R S S S MSSA S
155 104865 OP 64 M LOW ECZEMA SEC 1 S.aureus S S S S S S S S S MSSA S
156 21624 45 21 F LOW
PEMPHIGUS 
VULGARIS
SEC 1
Klebsiella 
pneumoniae
S R S S S R S S ESBL
157 123203 OP 46 M LOW CARBUNCLE PRI 2
Pseudomonas 
aeruginosa 
S S R S S S S S
E.coli S R S S S S R S S ESBL
158 122165 OP 53 F LOW FOLLICULITIS PRI 1 S.aureus R R R S R R S S S MSSA S
159 42356 44 55 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S R R R R S S S MSSA S
160 95373 44 40 M LOW
PSORIASIS 
VULGARIS
SEC 1 CoNS R S S S R S S S S MSCoNS
161 69044 44 28 M LOW
NON-HEALING 
ULCER
SEC 1 S.aureus R S S S R R S S S MSSA S
162 77266 OP 62 M LOW TROPHIC ULCER SEC 1 S.aureus R S S S R S S S S MSSA S
163 169540 OP 66 M LOW
BULLOUS 
PEMPHIGOID
SEC 1 S.aureus R S S S S S S S S MSSA S
164 37389 OP 30 F LOW FURUNCULOSIS PRI 1 S.aureus R S R S R R S S S MSSA S
165 13913 44 38 M MIDDLE
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S R S S S S MSSA S
166 12204 OP 42 M LOW ECZEMA SEC 1 S.aureus R S S S R S S S S MSSA S
167 106952 OP 63 F LOW ECTHYMA PRI 1 S.aureus R S R S S S S S S MSSA S
168 1226421 OP 22 M LOW IMPETIGO PRI 1 S.aureus R S S S R S S S S MSSA S
169 43591 45 34 M LOW TROPHIC ULCER SEC 1 S.aureus R R R S R R R S R MRSA R R POSITIVE
170 80627 45 41 F LOW
PEMPHIGUS 
VULGARIS
SEC NG
171 96048 44 62 M LOW
BULLOUS 
PEMPHIGOID
SEC NG
172 448888 44 46 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R R R R S S S MSSA S
173 40623 45 23 F MIDDLE
PUSTULAR 
PSORIASIS
SEC 1 S.aureus R S S S S S S S S MSSA S
174 40785 45 37 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R S S R S S S S MSSA S
175 1149198 OP 36 M LOW IMPETIGO PRI NG
176 160318 OP 70 M LOW STASIS ULCER SEC 1 S.aureus R S R R R R S S R MRSA S S NEGATIVE
177 121493 OP 37 M LOW
INFECTED 
KELOID 
SEC 1 S.aureus R S S S R S S S S MSSA S
S. 
No.
IP No/OP 
No.
Wd. No./OP 
No.
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SINGLE/  TWO 
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organism isolated PEN GM ERY TET CIP COT CK LZ CX AK HLG VAN AMP OF PT CTX CEC CAZ IMP
RESISTANCE 
PATTERN
HL MU E TEST PCR mup A  
178 160436 OP 42 M LOW FURUNCULOSIS PRI 1 S.aureus S S S S S S S S S MSSA S
179 46294 44 48 M LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S S S S S S MSSA S
180 47698 45 40 F MIDDLE FURUNCULOSIS PRI 1 S.aureus R S S S R S S S S MSSA S
181 1240771 OP 63 M LOW ECZEMA SEC NG
182 97674 OP 70 M LOW CELLULITIS PRI NG
183 208118 OP 47 M LOW
NON-HEALING 
ULCER
SEC 1
Pseudomonas 
aeruginosa 
R R R R R S R S
184 48215 45 42 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S S R S S S MSSA S
185 122165 OP 53 M LOW FOLLICULITIS PRI 1 S.aureus R R R S R R S S S MSSA S
186 4801 OP 83 F LOW CELLULITIS PRI NG
187 191118 OP 75 M LOW ECTHYMA PRI 2 S.aureus R S R S S S R S S MSSA S
Pseudomonas 
aeruginosa 
R R R R S S S
188 129340 OP 19 F LOW IMPETIGO PRI 1 S.aureus R S R R R R S S S MSSA S
189 58968 44 70 M LOW
BULLOUS 
PEMPHIGOID
SEC NG
190 41629 45 39 F LOW IMPETIGO PRI NG
191 54924 44 56 M MIDDLE ECZEMA SEC 1 S.aureus S S S S R R S S S MSSA S
192 143721 44 67 M LOW STASIS ULCER SEC 1
Pseudomonas 
aeruginosa 
S S R R S S R S
193 54574 45 38 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R R R R R R S S S MSSA S
194 54726 13 57 F LOW
TROPHIC 
ULCER
SEC 1
Klebsiella 
pneumoniae
S S S S S S S S
195 106930 OP 18 F LOW FOLLICULITIS PRI NG
196 26765 44 18 M LOW
PEMPHIGUS 
VULGARIS
SEC NG
197 1271154 OP 50 M LOW ECZEMA SEC 1 S.aureus S S S S S S S S S MSSA S
198 55843 45 31 F LOW FOLLICULITIS PRI 1 S.aureus R S S S R S S S S MSSA S
199 55489 45 19 F LOW FURUNCULOSIS PRI 1 S.aureus R S S S S S S S S MSSA S
200 40783 45 39 F LOW
PEMPHIGUS 
VULGARIS
SEC 1 S.aureus R S S S S R S S S MSSA S
LEGENDS FOR MASTER CHART 
PEN  - PENICILLIN  
GM   - GENTAMICIN 
ERY  - ERYTHROMICIN 
TET - TETRACYCLINE 
CIP - CIPROFLOXACIN 
COT - COTRIMOXAZOLE 
CK - CHLORAMPHENICOL 
LZ - LINEZOLID 
CX - CEFOXITIN 
AK - AMIKACIN 
VAN - VANCOMYCIN 
HLG - HIGH-LEVEL GENTAMICIN 
AMP - AMPICILLIN 
OF - OFLOXACIN 
PT - PIPERACILLIN-TAZOBACTAM 
CTX - CEFOTAXIME 
CEC - CEFOTAXIME-CLAVULANIC ACID 
CAZ - CEFTAZIDIME 
IMP - IMIPENEM 
R - RESISTANT 
S - SENSITIVE 
M - MALE 
F - FEMALE 
PRI - PRIMARY 
SEC - SECONDARY 
MRSA - METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
MSSA -  METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS 
ESBL - EXTENDEDED SPECTRUM BETALACTAMASE 
MRCoNS -  METHICILLIN RESISTANT COAGULASE-NEGATIVE   
  STAPHYLOCOCCUS AUREUS 
MSCoNS -  METHICILLIN SENSITIVE COAGULASE-NEGATIVE   
  STAPHYLOCOCCUS AUREUS 
  
 
